

1 Gait and Balance Function Improves After 10 Weeks of Using a 2 Wearable Sensory Neuroprosthesis in Persons with Peripheral 3 Neuropathy and High Fall Risk – the walk2Wellness Trial

4 Lars IE Oddsson^{1,2,3}, Teresa Bisson^{2,4}, Helen S Cohen⁵, Laura Jacobs¹, Mohammad Khoshnoodi¹¹, Doris
5 Kung⁵, Lewis A Lipsitz^{6,7,8}, Brad Manor^{6,7,8}, Patricia McCracken⁹, Yvonne Rumsey¹, Diane M Wrisley¹⁰, Sara
6 R Koehler-McNicholas^{2,9}.

7 ¹RxFnction Inc. MN, USA;

8 ² University of Minnesota, MN, USA;

9 ³ Ben Gurion University of the Negev, Israel;

10 ⁴ M Health Fairview, Minneapolis, MN, USA;

11 ⁵ Baylor College of Medicine, Houston, TX, USA;

12 ⁶ Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Roslindale, MA, USA.

13 ⁷ Division of Gerontology, Beth Israel Deaconess Medical Center, Boston, MA, USA;

14 ⁸ Harvard Medical School, Boston, MA, USA;

15 ⁹ Minneapolis Department of Veterans Affairs Health Care System, Minneapolis, MN, USA;

16 ¹⁰ College of St Mary, Omaha, NE, USA;

17 ¹¹ Johns Hopkins University School of Medicine, Baltimore, MD, USA;

18

19 Abstract

20 **Background:** Patients with sensory peripheral neuropathy (PN) commonly present with gait and balance
21 problems increasing their risk of falls. The multi-site walk2Wellness trial investigates effects of long-term,
22 home-based daily use of a wearable lower limb sensory neuroprosthesis on gait function, balance, quality of
23 life and fall rates in a cohort of PN patients. The device (Walkasins®, RxFnction Inc., MN, USA) is designed
24 to replace lost nerve function related to foot pressure sensation by providing directional tactile cues around the
25 ankle reflecting foot pressure measurements during standing and walking activities. We hypothesized that
26 previously shown short-term in-clinic improvements in gait and balance would be sustained after 10 weeks of
27 use.

28 **Methods:** Participants had a PN diagnosis with loss of plantar sensation associated with gait and balance
29 problems, a Functional Gait Assessment (FGA) score <23 (cut-off for high fall risk), and ability to sense Leg
30 Unit tactile stimuli. Clinical outcomes included FGA, Gait Speed, Timed Up&Go (TUG) and Four-Stage
31 Balance Test. Patient-reported outcomes included Activities-Specific Balance Confidence (ABC) scale,
32 Vestibular Disorders Activities of Daily Living Scale (VADL), PROMIS participation and satisfaction scores,
33 pain rating, and falls. Evaluations were performed at baseline visit and after 2, 6, and 10 weeks. Subjects were
34 not made aware of any changes in outcomes and no additional balance interventions were allowed.

35 **Results:** Forty-five participants of 52 enrolled across four sites completed all in-clinic assessments. FGA
36 scores improved from 15.0 at baseline to 19.1 at 10 weeks ($p<0.000001$), normal and fast gait speed from
37 0.86m/s to 0.95m/s ($p<0.00005$) and 1.24m/s to 1.33m/s ($p<0.002$), respectively, and TUG from 13.8s to 12.5s
38 ($p<0.012$). Four-Stage Balance Test did not improve significantly. Several patient-reported outcomes were in
39 normal range at baseline and remained largely unchanged. Interestingly, while FGA scores improved similarly
40 across the baseline range, subjects with baseline ABC scores lower than 67% (cut-off for high fall risk)
41 showed an increase in their ABC scores (from 49.9% to 59.3%, $p<0.01$), whereas subjects with baseline ABC
42 scores above 67% showed a decrease (from 76.6% to 71.8%, $p<0.019$). Subjects who reported falls in the prior
43 six months ($n=25$) showed a decrease in the number of fall-risk factors (from 5.1 to 4.3, $p<0.023$) as well as a
44 decrease in fall rate from 13.8 to 7.4 falls/1000 days ($p<0.014$). Four subjects in the pre-study non-faller group
45 ($n=20$) fell during the 10 weeks of the study.

46 **Conclusion:** A wearable sensory neuroprosthesis may provide a new way to treat gait and balance problems
47 and manage falls in high fall-risk patients with PN.

48 **Trial registration:** ClinicalTrials.gov (#NCT03538756)

49

50 **Keywords:** Peripheral Neuropathy, Falls, Neuroprosthesis, Balance, Gait Speed, Function,
51 Neuromodulation, Clinical Trial

52

Wearable Sensory Neuroprosthesis for Balance

53 1 Introduction

54 Falls are a widely recognized problem in the elderly (Ganz and Latham, 2020). About 29% of
55 community-dwelling adults 65 years or older fall once annually and 10% fall at least twice annually
56 (Ganz et al., 2007; Bergen et al., 2016). Data from the Centers for Disease Control (CDC) indicate
57 that medical treatment was required by 37.5% of individuals who fell in 2014 (Bergen et al., 2016).
58 Sterling et al. (Sterling et al., 2001) reported that 30% of falls in the elderly result in serious injury. In
59 2015, medical cost related to fatal and nonfatal falls was approximately \$50.0 billion (Florence et al.,
60 2018). Overall, falls are associated with poor health, shortened survival (Jónsdóttir and Ruthig,
61 2020), reduced quality of life, and a fear of falling (Lawrence et al., 1998; Scheffer et al., 2008).
62 Sensory peripheral neuropathy (PN) is associated with poor balance and is an independent risk factor
63 for falls (Richardson and Hurvitz, 1995), regardless if the etiology is idiopathic (Riskowski et al.,
64 2012), due to diabetes (Mustapa et al., 2016; Vinik et al., 2017), or chemotherapy (Winters-Stone et
65 al., 2017). The prevalence of PN in the US population for those over age 40 has been reported to be
66 nearly 15% (Gregg et al., 2004). The importance of sensory information from plantar cutaneous
67 mechanoreceptors for balance control has been shown in healthy individuals (Meyer et al., 2004a; b),
68 with loss of such information in patients with PN likely leading to problems with gait and balance
69 function and increased risk of falls (Menz et al., 2004; DeMott et al., 2007; Dixon et al., 2017;
70 Lipsitz et al., 2018). The occurrence of fall-related injuries is up to 15 times higher in patients with
71 diabetic PN than in healthy individuals (Cavanagh et al., 1992). Furthermore, the prevalence of
72 polyneuropathy has been reported to be almost four times higher in persons older than 60 years and
73 to independently contribute to functional impairments including difficulty walking and tendency to
74 fall (Hoffman et al., 2015). Persons with polyneuropathy are more likely to fall and more often incur
75 fall-related injuries (Hanewinkel et al., 2017). In a prospective study, 65% of older individuals with
76 PN fell during a one-year period and 30% reported an injury from a fall (DeMott et al., 2007). In
77 addition, low gait speed is a risk factor for falls (Studenski et al., 2003; Montero-Odasso et al., 2005),
78 an important indicator of frailty (Kim et al., 2019) and a predictor of survival (Studenski et al., 2011).
79 Although gait speed declines with healthy aging (Buracchio et al., 2010), the decline in individuals
80 with progressive sensory loss may be four times as high (Lipsitz et al., 2018). Interestingly,
81 interventions designed to improve gait speed may also increase survival (Hardy et al., 2007).
82

83 Clinical treatment of gait and balance problems related to PN is mainly limited to the use of canes,
84 walkers, physical therapy interventions and balance exercises (Richardson et al., 2001; Ganz and
85 Latham, 2020) including Tai-Chi (Li and Manor, 2010; Manor et al., 2014; Quigley et al., 2014).
86 Long-term use of bilateral ankle foot orthoses in elderly individuals with a history of falls showed
87 positive changes in certain in-clinic static sway measures (Wang et al., 2019a), although long-term
88 benefits related to fall rates and gait function appear limited (Wang et al., 2019b).
89

90 Several review studies support the hypothesis that strength and balance training interventions can
91 improve balance and reduce fall risk and falls in patients with PN (Ites et al., 2011; Tofthagen et al.,
92 2012; Streckmann et al., 2014). The training, however, should be specific to balance (Bulat et al.,
93 2007; Oddsson et al., 2007; Halvarsson et al., 2011; Akbari et al., 2012) because strength and/or
94 endurance training in patients with PN appears to have less impact on balance (Streckmann et al.,
95 2014). In addition, unless balance activities, including Tai Chi or balance therapies are conducted
96 with sufficient intensity, frequency (Lipsitz et al., 2019) and specificity, benefits may be limited or
97 absent (Kruse et al., 2010; Lipsitz et al., 2018; Lipsitz et al., 2019) leading to mixed outcomes.
98 Furthermore, continued exercise is required to maintain benefits long-term (Wolf et al., 2001;
99 Halvarsson et al., 2013; Melzer and Oddsson, 2013), although some improvements last up to six

Wearable Sensory Neuroprosthesis for Balance

100 months (Allet et al., 2010). Guidelines regarding physical activity for older adults with mobility
101 problems recommend a minimum of activity at least twice a week (Chodzko-Zajko et al., 2009).
102 Some studies on patients with diabetic PN following a period of balance training 2-3 times /week
103 over 6-12 weeks did show improved balance and reduced fall risk (Morrison et al., 2010; Morrison et
104 al., 2018). However, there currently are no specific guidelines regarding frequency of balance
105 exercises and even three times a week may be insufficient to see an improvement in balance function
106 (Kruse et al., 2010). Consequently, there is a need for additional solutions to help improve gait and
107 balance function in patients with PN.
108

109 A growing body of literature on various sensory substitution and augmentation technologies suggest
110 novel ways of improving gait and balance function in different populations of patients. The concept
111 of sensory substitution related to brain plasticity was laid out by Bach-y-Rita and colleagues, initially
112 for vision and the vestibular system (Bach-y-Rita et al., 1969; Bach-y-Rita, 2004) and other sensory
113 systems (Tyler et al., 2003; Bach-y-Rita, 2004). Recent efforts include wearable systems showing
114 benefits to patients with vestibular loss (Hegeman et al., 2005; Wall et al., 2009; Basta et al., 2011;
115 Yamanaka et al., 2016), PN (Wall et al., 2012; Wrisley et al., 2018) and Parkinson's Disease (Rossi-
116 Izquierdo et al., 2013; Lee et al., 2015). Combining wearable neurostimulation with balance therapy
117 has shown benefits in patients with multiple sclerosis (Leonard et al., 2017), cerebellar ataxia (Cakrt
118 et al., 2012), stroke (Badke et al., 2011) traumatic brain injury (Ptito et al., 2020) and in-home
119 balance therapy (Bao et al., 2018)
120

121 In a randomized crossover trial, a recent study further supported findings from an earlier pilot study
122 (Wall et al., 2012) and demonstrated meaningful short-term, in-clinic improvements in Functional
123 Gait Assessment (FGA) scores and gait speed in subjects with PN using a wearable sensory
124 neuroprosthesis (Koehler-McNicholas et al., 2019). The device (Walkasins®, RxFunction Inc., MN,
125 USA, Figure 1) is an external lower limb sensory prosthesis designed to replace lost nerve function
126 used for detection and signaling of foot pressure sensation in patients with PN. It provides gentle
127 directional tactile stimuli (in the form of low-intensity vibrations) around the lower leg that reflect
128 changes in foot pressure distribution measured with an instrumented Foot Pad in the shoe. The
129 subject's nervous system senses these new tactile cues and incorporates them to improve gait and
130 balance. Currently, effects of long-term daily use of Walkasins on clinical outcomes are unknown.
131 The multi-site clinical trial, walk2Wellness, (NCT #03538756, www.clinicaltrials.gov) investigates
132 long-term, home-based use of Walkasins on clinical and patient-reported outcomes of balance and
133 gait function, quality of life, physical activity, social participation, pain and fall rates. Data from the
134 primary endpoint of the study at 10 weeks are reported here. We hypothesized that previously
135 demonstrated short-term in-clinic improvements in FGA score by at least four points would be
136 sustained long-term (Beninato et al., 2014; Koehler-McNicholas et al., 2019). Early data from the
137 trial were presented in abstract form (Oddsson et al., 2019; Oddsson et al., 2020a).
138

Wearable Sensory Neuroprosthesis for Balance

139 2 Materials and Methods

140 2.1 Subject Recruitment

141 Human subject testing was approved according to the Declaration of Helsinki by Advarra IRB
142 (formerly Quorum Review IRB), serving as the Institutional Review Board (IRB) of record for three
143 of the participating sites under the study protocol for *walk2Wellness: Long-term Use Effects of*
144 *Walkasins® Wearable Sensory Prosthesis on Gait Function, Balance-Confidence, and Social*
145 *Participation*. The three sites include Baylor College of Medicine, Houston, TX; Hebrew SeniorLife,
146 a Harvard Medical School Affiliate, Boston, MA; and M Health Fairview, Minneapolis, MN.
147 Advarra IRB determined that Walkasins are a non-significant risk device because they do not meet
148 the criteria of a significant risk device according to U.S. Food and Drug Administration regulations.
149 The IRB Subcommittee, the Subcommittee on Research Safety, and the Research and Development
150 Committee of the Minneapolis VA Health Care System (MVAHCS) also approved the trial. The
151 study is registered on ClinicalTrials.gov (#NCT03538756). At the time this study began, Walkasins
152 were available only for research purposes.

153 2.2 Inclusion and Exclusion Criteria

154 Inclusion criteria for the study were similar to Koehler-McNicholas et al. (Koehler-McNicholas et al.,
155 2019): age 21-90 years; male or female; a formal diagnosis of sensory PN prior to participating in the
156 study as indicated by subject's medical record or a signed letter by a physician; self-reported
157 problems with balance; ability for transfers or ambulation on level surfaces at fixed cadence as
158 assessed by trained study personnel; an Functional Gait Assessment (FGA) score <23, the cut-off
159 score for high fall risk (Wrisley and Kumar, 2010); ability to understand and provide informed
160 consent; foot size to allow the Walkasins device to function properly, and ability to complete all
161 functional outcome measures without the use of an assistive device to ensure sufficient motor
162 function. Subjects could use an assistive device at their own discretion during the trial. Subjects were
163 excluded from participation if they were unable to perceive tactile stimuli from the Walkasins leg
164 unit or used an ankle-foot orthosis for ambulation that prevented donning of the device. Subjects with
165 any of the following conditions were also excluded: acute thrombophlebitis; deep vein thrombosis;
166 untreated lymphedema; a lesion of any kind, swelling, infection, inflamed area of skin, or eruptions
167 on the lower leg near placement of the device; foot or ankle fractures; or severe peripheral vascular
168 disease. In addition, subjects with any musculoskeletal or other neurological conditions that would
169 prohibit use of the device, as determined by a clinician, were excluded. Due to risk of overloading the
170 pressure sensor Foot Pad, subjects weighing over 136 kg (300lbs) were excluded from participation.
171 Furthermore, subjects were prohibited from initiating any balance training (e.g., Tai-Chi etc.) or
172 balance-related therapy during the ten weeks of the trial. Subjects were not systematically provided
173 information about changes in any outcomes scores or changes in their performance throughout the 10
174 weeks of the trial, nor did study personnel monitor outcomes during the study. Potential subjects
175 responded to announcements that specifically targeted individuals with PN and balance problems, or
176 they were referred by clinicians who were familiar with the study and believed them to be good
177 candidates for the trial.

178 2.3 Study Procedures

179 All participants signed IRB-approved consent forms prior to the initiation of study activities.
180 Following the informed consent process, a study team member tested the subjects on both legs to
181 determine whether they could feel the stimuli from the Walkasins Leg Unit (Figure 1). Subjects wore

Wearable Sensory Neuroprosthesis for Balance

182 Walkasins on both feet. A small number of subjects who were unable to perceive the stimuli from the
183 Walkasins Leg Unit (Figure 1) were excluded from participation in the study. Participants then
184 completed a demographics and health screening questionnaire to assess common health issues related
185 to neurological, musculoskeletal, cardiopulmonary disorders, and other systemic diseases along with
186 information on their history of falls over the past six and twelve months and regular use of an
187 assistive device (Koehler-McNicholas et al., 2019). Falls were defined according to the World Health
188 Organization: “an event which results in a person coming to rest inadvertently on the ground or floor
189 or other lower level”. Subjects enrolled in the study were instructed to wear the device as much as
190 possible throughout their daily activities, indoors as well as outdoors. At each follow-up visit,
191 participants were asked about changes in their health status and any falls and adverse events they
192 experienced since the previous visit. During the baseline visit, participants also provided a list of
193 their medications (medication name, indication, dose, and frequency), which was updated over the
194 course of the study. Medications are a known risk factor for falling, based on side effects of
195 medication use or drug interactions (Woolcott et al., 2009).

196 **2.4 Initial Assessments**

197 Subjects then completed the Activities-Specific Balance Confidence (ABC) Questionnaire, which
198 measures levels of balance confidence in elderly persons. The ABC asks the question “How
199 confident are you that you will not lose your balance or become unsteady” when performing 16
200 different tasks (Powell and Myers, 1995). Subjects rated themselves on a scale from 0 to 100, and an
201 average score was calculated across the 16 responses. An ABC score below 67% has been associated
202 with high fall risk (Lajoie and Gallagher, 2004). In addition, subjects completed the Vestibular
203 Activities of Daily Living Scale (VADL) (Cohen et al., 2000), which evaluates self-reported effects
204 of vertigo and balance disorders on independence in everyday activities of daily living that are
205 relevant for individuals living in the community. Individuals rate their level of functional ability for
206 basic and instrumental activities of daily living on a scale from 1 (independent) to 10 (dependent),
207 which incorporates the use of assistive devices.
208

209 Following completion of the questionnaires, a study team member performed tactile and vibration
210 sensation testing to document loss of sensation. Loss of sensation was tested with the Weinstein
211 Enhanced Sensory Test (WEST) monofilament foot test (0.5g, 2g, 10g, 50g, and 200g) applied
212 perpendicular to the skin at four test sites on the plantar surface of the foot, including the first, third,
213 and fifth metatarsal heads as well as the great toe. Study personnel began testing with the 10g
214 filament and used a smaller filament if the subject was sensate and a larger filament if the subject was
215 insensate. The smallest filament the subject was able to feel was recorded (if none were felt this
216 result was recorded as “none”). Vibration sensation was assessed with a Rydel-Seiffer tuning fork,
217 which is a 128Hz tuning fork with end weights that convert the tuning fork from 128 to 64 Hz. The
218 weights are scaled allowing a score 0-8 (lower scores indicating less sensation), allowing reliable
219 quantitative vibratory testing. Scores were read from the black triangle and rounded to the nearest
220 whole number. Vibration values ≤ 4 are categorized as abnormal at the first metatarsal joint
221 (Kästenbauer et al., 2004). The tuning fork was applied firmly and perpendicular to the lateral aspect
222 of the first metatarsophalangeal, lateral malleolus, and patella testing sites. The monofilament and
223 vibration tests were repeated at the 10-week visit.

224 **2.5 Clinical Outcome Measures**

225 Upon completion of the monofilament and vibration sensation testing, subjects performed a series of
226 functional outcome measures while wearing the device turned off (baseline). Tests were repeated at

Wearable Sensory Neuroprosthesis for Balance

227 weeks 2, 6, and 10. Subjects could rest as needed during the clinical assessments. For study purposes
228 the clinical outcomes were standardized and performed by study personnel who were trained by one
229 of the investigators (DW). Observation visits were conducted periodically during the study to ensure
230 standardization among the sites.
231

232 **Functional Gait Assessment (FGA):** The FGA (Wrisley et al., 2004) is the recommended clinical
233 outcome measure for walking balance based on current physical therapy Clinical Practice Guidelines
234 for outcome measures for adults with neurologic conditions (Moore et al., 2018). It is a reliable and
235 valid measure of gait function related to postural stability and has been shown to be effective in
236 classifying fall risk in older adults and predicting unexplained falls in community-dwelling older
237 adults (scores $\leq 22/30$) (Wrisley et al., 2004; Wrisley and Kumar, 2010). It has also been validated in
238 multiple neurological conditions (stroke, Parkinson's, vestibular conditions) (Lin et al., 2010; Leddy
239 et al., 2011) and has less floor and ceiling effects than the similar Dynamic Gait Index (Lin et al.,
240 2010). The FGA includes 10 different items that challenge gait balance where each item is scored
241 from 0 to 3 (3 = normal, 2 = mild impairment, 1 = moderate impairment, 0 = severe impairment) with
242 a maximum score of 30. An increase of ≥ 4 points is considered the Minimal Clinically Important
243 Difference (MCID) for community-dwelling elderly individuals (Beninato et al., 2014). Subjects
244 whose baseline FGA score was 23 or higher were excluded from further participation in the study.
245 Subjects completed the FGA in a large open area with a 6-m (20-ft) walkway marked with tape
246 according to published recommendations (Wrisley et al., 2004).
247

248 **10-Meter Walk Test (10MWT):** The 10m-walk (Perera et al., 2006) is the recommended clinical
249 outcome measure for walking speed based on current physical therapy Clinical Practice Guidelines
250 for outcome measures for adults with neurologic conditions (Moore et al., 2018). It is routinely used
251 in rehabilitation and has excellent reliability in multiple neurologic conditions (chronic stroke,
252 traumatic brain injury, Parkinson's) (Hiengkaew et al., 2012). Gait speed has been found to be an
253 important predictor of survival in older adults (Hardy et al., 2007), further emphasizing its
254 importance as a clinical outcomes measure. Gait speed was assessed during the middle 6 meters of a
255 10-meter-long pathway to allow for acceleration and deceleration, completed in one trial under two
256 conditions: 1) walk at normal speed and 2) walk as fast as possible. An increase by 0.05 m/s is
257 deemed "small meaningful" and 0.10 m/s as "substantial" (Perera et al., 2006). These are considered
258 the MCID in the geriatric population (Perera et al., 2006).
259

260 **Timed Up and Go (TUG):** The TUG (Mathias et al., 1986) is part of the CDC recommended
261 STEADI test protocol for balance function (CDC, 2017). It is commonly used in rehabilitation and
262 has excellent validity and reliability for elderly adults and has been shown to be effective in
263 classifying community dwelling adults at risk for falls (Podsiadlo and Richardson, 1991; Shumway-
264 Cook et al., 2000; Bischoff et al., 2003; CDC, 2017). From a seated position in a standard armchair,
265 the subject is asked to do the following: 1) stand up from the chair, 2) walk at normal pace around a
266 tape mark on the floor 10 feet from the chair, 3) turn, 4) walk back to the chair at a normal pace, and
267 5) sit down again. Subjects were provided one practice trial that was not recorded followed by the
268 recorded timed trial. The tester recorded the time from the command "Go" until the subject's
269 buttocks returned to the chair when sitting. We used >12 s as a cut-off for high fall risk (Bischoff et
270 al., 2003; CDC, 2017). The Minimal Detectable Change (MDC) for older adults with type 2 diabetes
271 has been reported to be 1s (Alfonso-Rosa et al., 2014).
272

273 **4-Stage Balance Test:** The 4-Stage Balance Test is part of the Centers for Disease Control and
274 Prevention (CDC)-recommended STEADI test protocol for balance function (CDC, 2017). It

Wearable Sensory Neuroprosthesis for Balance

275 includes four gradually more challenging postures the subject is exposed to: 1) stand with feet side by
276 side, 2) stand with feet in semi-tandem stance, 3) stand with feet in tandem stance, and 4) stand on
277 one leg. Subjects were allowed upper extremity support to obtain the position and passed each level
278 if they were able to hold the stance unsupported for 10 seconds. The assessment ended when subjects
279 were unable to hold a stance for 10 seconds. The times for each position held was recorded and
280 summed as a measure of overall performance. A fail of stances 1, 2, or 3 (i.e., total time < 30s)
281 indicates high risk of falling (CDC, 2017).

282 **2.6 Learning Protocol**

283 As part of the baseline visit, subjects performed a standardized set of balance activities, once while
284 wearing the device turned off and once while wearing it turned on (Koehler-McNicholas et al., 2019).
285 Activities lasted approximately 10 minutes and included standing (two-leg standing, tandem
286 standing, and one-legged standing) and walking (walking straight, turning right and left) at both
287 normal and fast speeds. Activities were repeated with the eyes closed. During standing exercises
288 subjects were challenged to explore their base of support in both mediolateral and anteroposterior
289 directions and to notice the pattern of tactile stimuli when the device was turned on. During walking
290 activities subjects were instructed to notice the pattern of tactile stimuli when the foot was in contact
291 with the ground, how it matched their pace of walking, and the flow of tactile stimuli from step to
292 step. Subjects were not instructed how to respond to the tactile stimuli from Walkasins instead, the
293 activities focused on orientation and familiarization with the device.

294 **2.7 Participant Reported Outcomes**

295 At the baseline visit and at each follow-up visit at weeks 2, 6, and 10, subjects also completed the
296 five subject-reported outcome measures described below:

297
298 **Patient Health Questionnaire (PHQ-9):** The PHQ-9 (Kroenke et al., 2001) is a concise, self-
299 administered tool for assessing depression. Commonly used for screening and diagnosis of
300 depression, the PHQ-9 incorporates depression criteria according to the 4th edition of the Diagnostic
301 and Statistical Manual of Mental Disorders (DSM-IV) with other leading major depressive
302 symptoms.

303
304 **PROMIS Pain Interference Short Form 6b** (Askew et al., 2016): The PROMIS Pain Interference
305 instrument measures the self-reported impact of pain on relevant aspects of a person's life within the
306 past seven days. Items capture the extent to which pain hinders social, cognitive, emotional, physical,
307 and recreational activities. The Pain Interference short form is a global scale rather than disease
308 specific.

309
310 **PROMIS Numeric Rating Scale v1.0 - Pain Intensity Form 1a:** The PROMIS Pain Intensity
311 instrument assesses reported average pain intensity on a scale from 0-10 with higher scores indicating
312 greater levels of pains. The Pain Intensity short form is global rather than disease specific.

313
314 **PROMIS Ability to Participate Short Form 8a:** The PROMIS Ability to Participate in Social
315 Roles and Activities instrument (Hahn et al., 2016b) assesses the individual's perceived ability to
316 perform usual social roles and activities. The measure does not use a designated time frame (e.g. over
317 the past seven days), and higher scores represent fewer limitations (e.g., I have trouble doing all of
318 my regular leisure activities with others).

319

Wearable Sensory Neuroprosthesis for Balance

320 **PROMIS Satisfaction with Participation in Social Roles Short Form 8a:** The PROMIS
321 Satisfaction with Social Roles and Activities (Hahn et al., 2014; Hahn et al., 2016a) is a self-reported
322 instrument to assess satisfaction with the ability to perform usual social roles and activities (e.g., “I
323 am satisfied with my ability to do things for my family”).

324 PROMIS scores are presented as T-scores, a standardized score with a mean of 50 (representing
325 average for the US population) and a standard deviation of 10.
326

327 **User Experience Survey:** At the 2 and 10-week visits, subjects completed a 10-question survey to
328 collect information concerning their experience with the device. Subjects rated aspects of Walkasins
329 use (e.g., donning and doffing, charging, etc.) on a 7-point Likert scale ranging from “Very Easy” to
330 “Very Hard”. Subjects also rated their overall satisfaction with the device and were able to provide
331 additional comments and feedback regarding their experience with the device. Between visits,
332 subjects were asked to document their use of Walkasins on a calendar by marking the days they wore
333 their Walkasins and for how many hours. The subject calendar was also used to facilitate
334 documentation of falls that occurred over the course of the study (Hannan et al., 2010). Subjects were
335 asked to return their calendars at their next study visit.

336 **2.8 Number of Subjects**

337 Sample size estimation was based on data from the recent study of a similar population of subjects
338 (Koehler-McNicholas et al., 2019), showing a baseline average FGA score of 15.2 and standard
339 deviation 4.8. The data was normally distributed according to the Shapiro-Wilk’s test. To detect a
340 mean difference in pre- and post-FGA score ≥ 4 points, the Minimal Clinically Important Difference
341 for community dwelling elderly individuals (Beninato et al., 2014), required at least 20 subjects using
342 a significance level of 0.01 and a power of 0.8. Accounting for an expected ~20% drop-out rate
343 (National Heart, 2020) target enrollment was set at 25 subjects ($20/0.8=25$). Multiple sites were
344 engaged in the trial to expand geographical, ethical, and clinical variation in the data initially
345 allowing each site to recruit up to 25 subjects. Due to the COVID-19 pandemic, the trial was
346 interrupted and continued enrollment as well as in-clinic testing was halted. At this time, sufficient
347 overall statistical power based on the sample size calculation above has been achieved following
348 enrollment of 52 subjects, well over the 20 subjects required to achieve statistical significance.
349 Collection of participant-reported outcomes has continued through phone calls and the longer-term
350 outcomes assessments as originally planned (at 26 and 52 weeks) are expected to continue.

351 **2.9 Statistical Analysis and Availability of Data**

352 Descriptive statistics were calculated and presented as mean and standard deviation of the mean.
353 Variables were tested for normality using the Shapiro-Wilk’s test. The two-proportion Z-test was
354 used to compare proportion-based measures. Subjects who reported falls in the previous six months
355 (Pre-Fallers, n=30) were analyzed separately from the remaining subjects (Pre-NonFallers, n=22).
356 Comparisons of baseline characteristics between Pre-Fallers and Pre-NonFallers were made with a t-
357 test for independent samples or a Mann-Whitney U test if data was not normally distributed based on
358 a Shapiro-Wilk’s test. Repeated measures analysis of variance (ANOVA) was performed for
359 outcomes measured across the four assessment events, baseline, 2, 6 and 10 weeks. If the ANOVA
360 was significant ($p < 0.05$), three pairwise comparisons were made using dependent t-tests between the
361 baseline assessments and each of the 2, 6 and 10-week assessments. If the ANOVA was non-
362 significant, no further comparisons were made. A Bonferroni’s adjustment of significance levels for
363 correlated measures was applied, ranging from $p < 0.0167$ ($0.05/3$ for three comparisons) for a full
364 correction (non-correlated measures, $r=0$) and $p < 0.05$ for perfectly correlated measures ($r=1$).

Wearable Sensory Neuroprosthesis for Balance

365 (Uitenbroek, 1997). Effect sizes were calculated using Cohen's d (Lakens, 2013) and were
366 interpreted according to recommendations by Cohen (Cohen, 1988) with 0.2 representing a small
367 effect, 0.5 a medium effect, and 0.8 a large effect. Ninety-five percent confidence intervals of effect
368 sizes were estimated according to Algina (Algina et al., 2005). Statistical analysis was performed
369 using the Analysis-ToolPak module in Microsoft Excel 2016 and the Real Statistics Resource Pack
370 software, release 6.8 (Zaiontz, 2020). Table 1 shows baseline characteristics of subjects enrolled in
371 the study from the four different clinical sites. Subject data were pooled for the continued analysis
372 presented here.
373 Datasets from the current study are available upon request. The raw data supporting the conclusions
374 of this article will be made available to qualified researchers, without undue reservation.
375

Wearable Sensory Neuroprosthesis for Balance

376 3 Results

377 3.1 Enrollment and Allocation

378 The flow chart for the study is shown in Figure 2. Sixty-seven subjects were assessed for eligibility
379 across the four participating sites. Their respective baseline characteristics are shown in Table 1. First
380 enrollment occurred at the MVAHCS on 10/22/2018, followed by M Health Fairview/University of
381 Minnesota on 10/23/2018, Baylor College of Medicine on 12/20/2018 and Marcus Institute/Harvard
382 Medical School on 09/19/2019. The last enrollment occurred at Baylor College of Medicine on
383 01/10/2020. Subjects across the four sites were pooled for the continued analysis presented here.
384 Fifteen subjects were excluded from participation of which five had an FGA score higher than 22;
385 two were unable to sense tactile stimuli from the device; two had neurological conditions that
386 prevented device use; two were planning to start physical therapy treatment, one declined to
387 participate and three for other reasons. Fifty-two subjects were enrolled for baseline assessment and
388 allocated for the intervention. A total of seven subjects discontinued participation, four subjects at the
389 two-week assessment (two related to device use, one due to transportation issues, and one due to an
390 unrelated adverse event, Figure 2), one ahead of the six-week assessment and two ahead of the 10-
391 week assessment (due to device and study issues), respectively (Figure 2). A total of 45 subjects
392 (87%) completed all in-clinic assessments from baseline to the 10-week endpoint.

393 3.2 Baseline Characteristics and Outcomes

394 Table 2 shows baseline characteristics of all enrolled participants (n=52), then separately for subjects
395 who reported having fallen in the six months preceding the study (Pre-Faller, n=30) and those who
396 did not report a fall (Pre-NonFaller, n=22). Overall, participants were elderly (74.4 ± 8.7 yrs.),
397 overweight ($BMI > 25$) and mostly male (79%). A majority used an assistive device (54%) and had
398 fallen in the previous year (71%) or in the past six months (58%). Furthermore, a majority showed
399 high fall risk based on low 4-Stage Balance Test outcomes (63% of subjects < 30s) (CDC, 2017) or
400 low ABC scores (56% of subjects scored < 67%) (Lajoie and Gallagher, 2004). Twenty-five percent
401 of participants had a normal gait speed less than 0.7 m/s (Montero-Odasso et al., 2005) and half of
402 the participants performed the TUG slower than 12 s (CDC, 2017), the commonly used thresholds for
403 high fall risk. The Pre-Faller group had a higher number of fall-risk factors as compared to the Pre-
404 NonFaller group (5.3 ± 1.0 , vs. 3.5 ± 1.3 , respectively, $p < 0.000001$). The baseline FGA score was
405 statistically significantly lower in Pre-Faller (13.5 ± 3.7) as compared to Pre-NonFaller (16.7 ± 3.6 ,
406 $p < 0.004$). There was no difference in normal gait speed between the two groups ($p = 0.12$), although
407 fast gait speed was higher in the Pre-NonFaller (1.41 ± 0.35 m/s) as compared to the Pre-Faller
408 subjects (1.13 ± 0.34 m/s, $p < 0.006$). Furthermore, TUG times were significantly slower in the Pre-
409 Faller group compared to the Pre-NonFaller (14.7 ± 6.3 s and 12.0 ± 2.9 , respectively, $p < 0.05$).
410

411 The ABC score was higher in the Pre-NonFaller compared to the Pre-Faller group, although the
412 difference was not statistically significant (66.0 ± 19.7 vs. 57.0 ± 15.2 , respectively, $p = 0.07$). The
413 VADL score was marginally lower in the Pre-NonFaller group (3.29 ± 1.02 , vs. 3.94 ± 1.04 , $p < 0.03$).
414 Pain scores were similar for the two groups (2.6 ± 2.1 vs. 2.9 ± 2.4). The PHQ-9 score was slightly
415 higher in the Pre-Faller group, although the difference was not statistically significant ($p = 0.11$).
416 PROMIS outcome scores for “Pain Interference,” “Satisfaction with Social Roles,” and “Ability to
417 Participate” (Table 2) showed mean values around 50 for both groups, which is considered average
418 for the US population (Askew et al., 2016; Hahn et al., 2016a; Hahn et al., 2016b). Any differences
419 were well within 10, which is one standard deviation of these measures in the US population (Table
420 2) (Askew et al., 2016; Hahn et al., 2016a; Hahn et al., 2016b).

Wearable Sensory Neuroprosthesis for Balance

421 3.3 Chronic Conditions and Medication Use

422 Table 3 shows self-reported chronic conditions and medication use for subjects enrolled in the study.
423 On average, subjects reported having 8.2 ± 3.3 chronic conditions. All subjects had a diagnosis of PN
424 either in their medical chart or provided in a letter signed by their physician. Most subjects reported
425 having neuropathic pain in their feet (73%) as well hypertension (63%) and half of participants
426 reported having chronic back pain. All subjects reported having difficulty with walking and balance.
427 The Pre-Faller group reported a higher incidence of cancer as a chronic condition than the Pre-
428 NonFaller group (43% vs. 14%, respectively, $p < 0.03$). Falls in the 12 months preceding study
429 participation were reported by all the Pre-Faller participants (i.e. reporting falls over the past 12 and
430 six months) versus by seven of the 22 in the Pre-NonFaller group (i.e. reporting falls over the past 12
431 but not six months) ($p < 0.00001$). Ninety percent of the falls reported in the 7-12 months preceding
432 the study were reported by the Pre-Faller participants ($p < 0.000001$). Overall, participants reported
433 taking one non-prescription medication and eight (median) prescription medications of which three
434 are known to cause potential balance issues and increase the risk of falling (Woolcott et al., 2009).
435 Medication use was similar between the Pre-Faller and Pre-NonFaller groups (Table 3).

436 3.4 Clinical Outcomes

437 Table 4 shows clinical outcomes for the 45 subjects who completed assessments at baseline, 2, 6 and
438 10 weeks. For all subjects, repeated measures ANOVA showed highly statistically significant
439 differences across the assessment events for all subjects and all clinical outcomes ($0.00001 < p <$
440 0.01) except for the 4-Stage Balance Test, which was not statistically significant ($p = 0.23$, Table 4
441 ANOVA column). Further pairwise comparisons following statistically significant ANOVA showed
442 highly statistically significant differences between the baseline assessment and the 2, 6, and 10-week
443 assessments, respectively, for the FGA score and normal gait speed and between baseline and 6 and
444 10 weeks, respectively, for fast gait speed and the TUG scores. Cohen's d effect size calculated
445 between the baseline and 10-week endpoint was large for FGA (0.92, FGA change from 15.0 to 19.1)
446 and small to medium for normal gait speed (0.42, 0.86m/s to 0.95m/s), fast gait speed (0.27, 1.24 m/s
447 to 1.33 m/s) and the TUG (0.28, 13.8 s to 12.5 s, Table 4).

448 Both the Pre-Faller and Pre-NonFaller groups increased their FGA scores from baseline to the 2-, 6-,
449 and 10-week assessments, respectively ($p < 0.00016$). The Pre-Faller group had lower FGA scores
450 both at baseline as compared to the Pre-NonFaller (13.5 vs. 16.9) and at the 10-week assessment
451 (16.8 vs. 22.0). Effect sizes for FGA changes for both groups were large, although higher in the Pre-
452 NonFaller group compared to the Pre-Faller group (Cohen's d 1.38 vs 0.82, respectively). Similarly,
453 normal gait speed increased for both groups although the effect size was larger in the Pre-NonFaller
454 group (Cohen's d 0.74 vs. 0.28, respectively). Interestingly, fast gait speed only improved in the Pre-
455 Faller group from 1.09 m/s at baseline to 1.17 m/s at 10 weeks ($p < 0.015$, Table 4) although effect
456 size was small (Cohen's d 0.27). There was an overall statistically significant change in TUG for the
457 Pre-Faller group (ANOVA, $p < 0.025$) although none of the pairwise comparisons reached statistical
458 significance required after Bonferroni correction ($0.047 < p < 0.14$). The overall ANOVA for TUG in
459 the Pre-NonFaller group was not statistically significant ($p = 0.49$, Table 4).

461 3.5 Participant Reported Outcomes, Sensation Tests, and Device Use

462 Patient reported outcomes for the 45 subjects who completed all assessments are shown in Table 5 as
463 well as for the Pre-Faller and Pre-NonFaller groups. For all subjects, there was an overall significant
464 ANOVA for the VADL score ($p < 0.044$) although none of the pairwise comparisons reached

Wearable Sensory Neuroprosthesis for Balance

465 statistical significance following Bonferroni correction ($0.053 < p < 0.99$). There were no other
466 statistically significant differences across all subjects during the 10-week period.
467

468 Table 5 shows and data from vibration sensation testing using the Rydel-Seiffer graduated tuning
469 fork for all subjects. There were no differences in vibration sensation between Pre-Faller and Pre-
470 NonFaller and no differences between baseline and 10-week assessments. Vibration sensitivity
471 showed bilateral symmetry across the three sites tested, right and left patella, lateral malleolus and
472 first metatarsophalangeal joints, respectively. There was a gradual proximal to distal decrease in
473 vibration sensitivity across the three sites from 4.3-4.4 proximally and 2.0 distally based on the 0-8
474 Rydel-Seiffer scale (Table 5). Similarly, there was bilateral symmetry for the WEST monofilament
475 sensitivity test. At baseline, the median for the monofilament test was 50g for both feet and across all
476 four anatomical test sites, the first, third, and fifth metatarsal heads as well as the great toe. This was
477 similar at the 10-week assessment with the exception for the first metatarsals of both feet where the
478 median monofilament increased to 200g.
479

480 In the Pre-Faller subgroup, there were no overall statistically significant differences for any of the
481 participant reported outcomes across the 10-week period (Table 5). For the Pre-NonFaller group,
482 there was a statistically significant difference in the PROMIS “Ability to Participate” score at two
483 weeks (ANOVA, $p < 0.04$, 49.7 ± 7.1 to 53.7 ± 7.3 , $p < 0.02$, Table 5). The improvement appeared
484 maintained at six (52.8 ± 7.6) and 10 weeks (53.7 ± 8.4) although it did not fully reach statistical
485 significance ($p < 0.06$). None of the other participant reported outcomes for the Pre-NonFaller group
486 were statistically different across the 10-week period (Table 5). Subjects reported using the device on
487 average 5.5 ± 1.4 days/week (range 3.5-7.0) for a total of 36.1 ± 14.9 hours/week (range 5.3-56.0).

488 **3.6 Falls Assessment**

489 Parameters related to falls and fall risk assessed at baseline and throughout the 10 weeks are shown
490 in Table 6. Overall, after 10 weeks, 13 of the 45 subjects had achieved FGA scores higher than 22,
491 the cut-off for normal fall risk (Wrisley and Kumar, 2010). Four of these subjects were part of the
492 Pre-Faller subgroup and nine were from the Pre-NonFaller group. Subjects reported a total of 62 falls
493 in the six months prior to the study. During the 10-week study period, 17 falls were reported, 13 of
494 which occurred in the Pre-Faller group and four in the Pre-NonFaller group (Table 6). Sixteen of the
495 25 Pre-Fallers did not fall during the 10-week period of the trial. There was a non-significant
496 decrease in fall rate across all subjects (from 7.7 to 5.4 falls/1000 patient days, $p < 0.27$). In the Pre-
497 Faller group, there was a 46% statistically significant decrease in fall rate (from 13.8 to 7.4 falls per
498 1000 patient days, $p < 0.014$). The Pre-NonFaller group showed a smaller non-significant increase in
499 fall rate (from 0 to 2.9 falls per 1000 patient days, $p = 0.125$). This increase was based on one fall each
500 by four subjects who had not fallen in the prior six months (Table 6). There was a statistically
501 significant decrease in the number of fall risk factors (Table 6) from baseline to 10 weeks across all
502 subjects (from 4.2 to 3.8 fall risk factors, $p < 0.047$). This decrease was larger and statistically
503 significant in the Pre-Faller group (from 5.1 to 4.3 fall risk factors, $p < 0.023$). There was no change in
504 the number of fall risk factors in the Pre-NonFaller group ($p = 0.76$, Table 6).
505

Wearable Sensory Neuroprosthesis for Balance

506 4 Discussion

507 4.1 Key Findings

508 Results from this multi-site clinical trial supported our *a priori* hypothesis that patients with gait and
509 balance problems due to sensory PN and high risk of falls would show clinically meaningful
510 improvements of gait and dynamic balance function after 10 weeks of using a wearable sensory
511 neuroprosthesis, confirming previously demonstrated in-clinic findings in a randomized controlled
512 cross-over trial (Koehler-McNicholas et al., 2019). Overall, the mean FGA score improved from 15.0
513 at baseline to 19.1 at 10 weeks across all subjects (Table 4), beyond the MCID for the FGA
514 (Beninato et al., 2014). Thirteen subjects reached normal fall risk status showing an FGA score
515 higher than 22 (Wrisley and Kumar, 2010) after 10 weeks of device use. Both normal and fast gait
516 speed improved overall by 0.09m/s, near what is considered substantial change (0.10m/s) for older
517 adults (Perera et al., 2006). Across both groups, TUG improved from 13.8 s to 12.5 s, which is
518 beyond the MDC for older adults with type 2 diabetes (Alfonso-Rosa et al., 2014). Effect sizes
519 ranged from large for FGA scores (Cohen's d, 0.92) to small for fast gait speed and TUG (0.27 and
520 0.28, respectively).

521 As expected, vibratory sensation did not improve during the trial suggesting new sensory information
522 from the device provided relevant input to improve function. Although both Pre-NonFallers and Pre-
523 Fallers showed improvements, effect sizes were larger in the Pre-NonFaller group for FGA and
524 normal gait speed while only the Pre-Faller group showed a statistically significant improvement in
525 fast gait speed with an effect size of 0.27. The increase in fast gait speed from 1.41 m/s to 1.52 m/s in
526 the Pre-NonFaller group did not reach statistical significance (ANOVA main effect, p=0.10),
527 although such gait speeds are considered in the high range of elderly community ambulators
528 (Middleton et al., 2015). Interestingly, the 4-Stage Balance measure, an indicator of static balance,
529 did not improve significantly over the 10-week period in either of the two subgroups although our
530 recent in-clinic study (Koehler-McNicholas et al., 2019) found a statistically significant improvement
531 in this measure in a group of PN patients. One important difference between these two groups may be
532 a slightly lower baseline static balance performance in the first cohort, a mean of 22.2 s versus 26.2 s
533 in the current one. The first group improved their performance in clinic to a mean of 27.6 s (p<0.001)
534 while they improved to a nearly identical 27.8 s (n.s.) in the current study. It may be that further
535 improvement of static balance performance would require some additional training challenge in
536 addition to device use (e.g. Romberg and sharpened Romberg types of activities) and simply wearing
537 the device daily does not sufficiently challenge the static balance ability assessed by the 4-Stage
538 Balance Test.

540 4.2 Physical Intervention versus Sensory Substitution

541 To our knowledge, this is the first trial where a cohort of subjects with gait and balance problems
542 related to PN have worn a sensory prosthetic device of this kind in the community and on a regular
543 basis. Other wearable neuromodulation technologies have been used as a treatment modality in a
544 home setting, although typically only worn in conjunction with a home therapy program for balance
545 and mobility in different categories of subjects, e.g., multiple sclerosis (Leonard et al., 2017) and
546 healthy elderly (Bao et al., 2018). A recent case study of a patient with PN wearing Walkasins for a
547 year (Wrisley et al., 2018), found dramatic improvements in gait and balance outcomes when daily
548 continuous device use was combined with balance therapy. The patient had received balance therapy
549 twice a week for over five months prior to using Walkasins and no longer noticed any further
550 improvements (Wrisley et al., 2018). In the current study, in an attempt to isolate the effect of long-

Wearable Sensory Neuroprosthesis for Balance

551 term device use on clinical outcomes, subjects were instructed to wear the device as much as possible
552 and were not allowed to participate in any additional balance training or therapy. Furthermore, they
553 were not systematically informed of any changes in their outcomes or performance, which they
554 would normally receive in regular clinical care. Still, improvements in clinical outcomes were similar
555 to those reported after various balance intervention programs conducted over comparable time
556 periods up to 12 weeks in similar patient populations (Shumway-Cook et al., 1997; Wolf et al., 2001;
557 Li et al., 2005; Manor et al., 2014), or even longer up to six months and nearly a year (Wolf et al.,
558 2003; Li et al., 2005; Li and Manor, 2010).

559
560 Interestingly, two systematic reviews of interventions specifically for patients with diabetic PN gave
561 lower extremity strengthening only a fair recommendation while other interventions showed
562 insufficient evidence to increase function (Ites et al., 2011; Tofthagen et al., 2012). More recently,
563 improvement in function in patients with PN following specific task-oriented training has been
564 shown (Salsabili et al., 2015). Consequently, it may be particularly difficult to enhance gait and
565 balance function in individuals with PN using physical therapy or balance training activities alone,
566 possibly because these interventions do not replace lost somatosensory input. Furthermore, effects of
567 a training or therapy program on gait and balance function are likely due to different mechanisms
568 than the use of a sensory substitution device.

569
570 For training/therapy programs to be effective, well known principles of training and exercise
571 physiology must be adhered to (Oddsson et al., 2007) ensuring that sensorimotor systems are
572 sufficiently challenged to adapt and improve their capabilities leading to improved muscle function
573 and neuromotor coordination. However, patients with PN have lost important cutaneous afferent
574 systems that typically would not be affected by such interventions. Instead, improvements related to
575 use of Walkasins seen in the current study are most likely due to participants receiving new tactile
576 balance stimuli that are relevant for gait and balance and therefore become integrated into their
577 neuromotor control and movement repertoire. Subjects in the current study received hundreds of such
578 stimuli per hour from the device during their regular standing and walking activities throughout the
579 day.

580
581 Consequently, we hypothesize that any balance-related therapy or training activity in conjunction
582 with wearing the device would provide an additive effect to overall function and balance outcomes.
583 This hypothesis is supported by our recent case study (Wrisley et al., 2018) as well as our previous
584 in-clinic study where subjects following a baseline assessment were randomized to either wearing the
585 device turned on or turned off while performing a brief 10-15 min standardized balance activity
586 session with a physical therapist (Koehler-McNicholas et al., 2019). Ten of 15 subjects in the on
587 group increased their FGA scores by at least 4 points compared to five of 16 in the off group
588 ($p < 0.05$). Furthermore, seven of 15 subjects in the on group increased gait speed by $>0.13\text{m/s}$
589 compared to 3 of 16 in the off group ($p < 0.05$) (Koehler-McNicholas et al., 2019).

590 4.3 The Importance of Gait Speed

591 Gait speed is a powerful indicator of overall health and survival in the elderly population and
592 improving gait speed is an important therapeutic goal. Based on a large population study, Studenski
593 et al. (Studenski et al., 2011) found that gait speed, age, and gender predicted survival as well as
594 factors related to chronic conditions, smoking history, blood pressure, and hospitalization. In fact,
595 improvement in gait speed by 0.10 m/s was found to predict better survival in older adults (Hardy et
596 al., 2007). Furthermore, while each decrease in gait speed by 0.10m/s has been associated with longer
597 hospital stays and higher healthcare costs, each 0.10m/s per year increase in gait speed has been

Wearable Sensory Neuroprosthesis for Balance

598 shown to be predictive of shorter hospital stays and healthcare cost reduction (Purser et al., 2005)
599 further emphasizing the importance of gait speed as a relevant health indicator and vital sign
600 (Middleton et al., 2015).

601
602 Healthy aging is associated with an annual decrease in gait speed by 0.013 m/s (Buracchio et al.,
603 2010). However, it is well known that individuals with PN walk slower than their healthy counterparts
604 (Menz et al., 2004; Lipsitz et al., 2018), likely as an adapted strategy to maintain balance (Dingwell
605 et al., 2000). In fact, subjects with peripheral sensory loss (Lipsitz et al., 2018) who were consistently
606 impaired over five years showed a decline in gait speed of 0.23 m/s over that time period, i.e., 0.046
607 m/s/yr., more than 3.5 times higher than reported by Buracchio in healthy aging (Buracchio et al.,
608 2010). Our current population of subjects with PN, who appear similar to the “impaired” category of
609 community-dwelling older individuals in Lipsitz et al. (Lipsitz et al., 2018), showed an increase in
610 gait speed of 0.09 m/s following 10 weeks of use of the Walkasins device, corresponding to an
611 annual rate of 0.47 m/s. Interestingly, the Pre-Faller group increased both their normal and fast gait
612 speed although the effect size was smaller compared to the Pre-NonFaller group who improved only
613 their normal gait speed.

614 4.4 Plantar Sensation and Balance Control

615 The improvement in gait speed and function from wearing Walkasins may be interpreted from our
616 understanding of the sensorimotor control of human locomotion and balance. When subjects with PN
617 perform gait and balance activities, sensory information related to foot pressure is either completely
618 absent or at least distorted and, therefore, likely non-veridical; and it is unlikely that remaining
619 balance-related somatosensory information can sufficiently compensate, leading to decreased
620 stability and increased risk of balance loss. Plantar cutaneous sensory information is important for
621 standing balance (Meyer et al., 2004b; Strzalkowski et al., 2018) gait stability (Zehr et al., 2014)
622 signaling stance limb placement and withdrawal to facilitate phase-dependent modulation of
623 controlling reflex responses (Zehr and Stein, 1999) as well as when responding to balance
624 perturbations (Meyer et al., 2004a). Hlavacka et al. (Hlavacka et al., 1995) stated that an internal
625 representation of the body vertical requires integration of somatosensory and vestibular inputs, later
626 emphasized by Bronstein who concluded that somatosensory information has a “prominent role” in
627 verticality perception, which is crucial for optimal balance control (Bronstein, 1999). Marsden et al.
628 (Marsden et al., 2003) concluded that the processing of vestibular information is influenced by load-
629 related afferent feedback for control of balance.

630
631 The integration of somatosensory and vestibular information appears of particular importance for gait
632 function during the double support phase following foot placement during walking (Bent et al.,
633 2004), which is near the events when Walkasins provides tactile stimuli. Although of lesser fidelity
634 than intact plantar sensation, the Walkasins device may provide sufficient and relevant sensory
635 information that is veridical both during standing and walking activities by signaling out of balance
636 events during standing as well as indicating stance and swing phases of gait, which can help improve
637 gait and balance function. Furthermore, these tactile stimuli are provided just proximally to the
638 original sensory loss and mainly along the same dermatomes representing the plantar surface of the
639 foot possibly making it intuitive to integrate into functional behavior (Koehler-McNicholas et al.,
640 2019) by providing relevant sensory information to spinal central pattern generators for locomotion
641 (Guertin, 2012).

642

643

Wearable Sensory Neuroprosthesis for Balance

644 4.5 Falls Data

645 Although we noticed an encouraging decrease in fall rate as well as in the number of fall-risk factors
646 in the Pre-faller subgroup (Table 6), a 10-week time period with a fairly small number of subjects is
647 too short to draw any final conclusions related to prevention of falls. Continued evaluation of longer-
648 term data from the walk2Wellness trial during continued use of the device is currently ongoing (26
649 and 52 weeks) and will be reported at a future date. Interestingly, studies have found that effects of
650 improved clinical gait and balance outcomes may lead to a delayed effect of fall reduction, which
651 was reported following six months of Tai Chi (Li et al., 2004; Li et al., 2005) and also observed by
652 Wolf et al. (Wolf et al., 1996; Wolf et al., 2003).

653 4.6 Participant Reported Outcomes

654 There appeared to be none or only minimal changes in the self-report measures throughout the 10
655 weeks of the trial (Table 5). Although this may seem counterintuitive, Richardson et al. (Richardson
656 et al., 2001) reported significant improvements in clinical balance outcomes, but non-significant
657 improvement in the ABC score following a strength and balance intervention for patients with PN.
658 Similarly, an exercise intervention study for older adults found discrepancies between balance and
659 ABC score improvements suggesting that the relationship between balance confidence and functional
660 performance may not be well understood (Cyarto et al., 2008). In the current study, a lack of overall
661 improvement in the ABC score may also be influenced by subject expectations, the short duration of
662 study, or the time of the year as some subjects were enrolled in the winter months during snowy and
663 icy conditions. Furthermore, results of the ABC balance confidence scores may also be viewed in the
664 context of the subjects not being systematically informed of changes in clinical outcomes during the
665 study, nor receiving any organized encouragement reflecting their performance.

666 Interestingly, upon further investigation we observed differences between the overall pattern of
667 improvement in clinical outcomes versus self-reported measures of balance confidence as illustrated
668 in Figure 3. Clinical outcomes at 10 weeks showed similar improvement across the full range of
669 baseline scores, indicated by a regression line between baseline and 10-week scores being near
670 parallel with the line of unity as illustrated with the FGA scores in Figure 3 A. However, this was not
671 the case for the balance confidence ABC-score as seen in Figure 3 B (similar observations were made
672 for the VADL scores, not shown here). As can be seen, the regression line between baseline and 10-
673 week ABC scores intersects the line of unity and it has a slope of 0.47 (Figure 3 B). Interestingly, the
674 two lines intersect at the baseline value 67%, the published cut-off value for high fall risk (Lajoie and
675 Gallagher, 2004).

676 Subjects enrolled in the current study were all at high fall risk based on their FGA score ≤ 22 (Wrisley
677 and Kumar, 2010) as well as a diagnosis of PN (Richardson and Hurvitz, 1995). Based on additional
678 outcomes and baseline characteristics, subjects had on average more than four fall risk factors (Table
679 1, Table 2, Table 6). Consequently, it could be argued that study participants with multiple
680 impairments related to balance maybe “should not” have a balance confidence ABC score above 67%
681 and those who report such scores are either overly confident and/or simply unaware of their true
682 balance capabilities. Compellingly, subjects with greater balance confidence at baseline actually
683 showed a decrease in their balance confidence during the study (from 76.5 ± 8.1 to 71.8 ± 9.9 , $p < 0.02$)
684 while subjects with a baseline ABC score $< 67\%$ (in the range of high-fall risk) increased their
685 balance confidence scores ($49.9 \pm 12.5\%$ to $59.3 \pm 15.1\%$, $p < 0.01$).
686

Wearable Sensory Neuroprosthesis for Balance

If we consider a simple ratio between ABC and FGA scores representing “amount” of balance confidence per FGA point, someone with 100% balance confidence and the maximum FGA score of 30 would have a ratio of 3.3. A ratio between the established cut-offs for high fall risk for ABC and FGA scores, 67% and 22, respectively, represents a ratio of 3.0. At baseline in the current trial, the overly confident subjects had a ratio of 5.1 ± 1.3 , versus 3.6 ± 1.1 for the low confidence subjects. After 10 weeks of device use, with increased FGA scores across the board, the ratio was 3.8 ± 1.4 for the overly confident subjects versus 3.4 ± 1.0 for the lower confidence subjects. It appears the overly confident subjects may have “normalized” their self-perception of their balance ability while the lower confidence subjects increased their ABC score proportionally to their improved FGA score and maintained a similar self-confidence to FGA ratio. Although the FGA and ABC capture different constructs related to balance, it may be of importance for clinicians to be aware of the potential discrepancy between a patient’s self-perception and actual functional performance when developing a plan of care targeting gait, balance function and fall prevention.

The T-scores for baseline PROMIS measures (Pain Interference, Satisfaction Social Roles, Ability to Participate) were all close to 50, which was unexpected since it is considered the average for the US population (Hahn et al., 2014; Askew et al., 2016; Hahn et al., 2016a; Hahn et al., 2016b). We had expected these outcomes to deviate significantly in this complex clinical population. Consequently, any major changes in these measures should not be expected although a small statistically significant improvement in PROMIS Ability to Participate score, which remained through 10 weeks, was seen for the Pre-NonFaller sub-group from baseline to the 2-week assessment.

Some additional trends in the patient reported outcomes of interest for further research were observed, especially some differences between the Pre-Faller and Pre-NonFaller group. The Pre-Faller group had a PHQ-9 score of 5.3 at baseline, >5 considered mild depression (Kroenke et al., 2001), which decreased to 3.9 at 6 weeks and reached 4.5 at 10 weeks, changes that nearly reached overall statistical significance ($p=0.08$), and of minimal clinical relevance (Kroenke et al., 2001). It may be of interest to further investigate individuals with higher initial PHQ-9 scores to better understand this observation. In the Pre-NonFaller group, a non-significant ($p=0.12$), increasing trend in PROMIS Satisfaction Social Roles scores and a near significant improvement in VADL score ($p=0.08$) were seen. Finally, while VAS Pain scores were overall in the range of mild pain (≤ 3) and remained steady throughout 10 weeks, pain scores appeared to trend slightly lower in the Pre-NonFaller group, although not statistically significant ($p=0.10$) and not clinically meaningful. Here it may be of interest to further investigate individuals with higher initial pain levels, especially those with neuropathy-related foot pain by using a more disease-specific pain rating scale.

4.7 Study Limitations

There are several limitations to this trial. It is not blinded, lacks a control group and a placebo treatment. Unfortunately, it is not feasible to blind subjects from treatment in the current study since being able to feel the tactile stimuli from the device is an inclusion criterion. Using some form of random pattern stimuli as a sham may seem possible (Basta et al., 2011), although it is not known if such stimuli may have an effect of their own and it would not help address the question whether using the device as currently designed, according to principles of sensorimotor control of balance and gait, has an effect on gait and balance function. Consequently, the best placebo treatment would likely be wearing a device that is turned off. However, without using some form of deceit claiming the device is working although it cannot be felt, it would likely be difficult to recruit participants for such research and/or to ensure long-term compliance. In addition, incorporating a minimal stimulation amplitude as a sham, assuming it has no effect may be incorrect since studies

Wearable Sensory Neuroprosthesis for Balance

736 implementing stochastic resonance using subsensory mechanical noise have demonstrated
737 improvement in balance (Lipsitz et al., 2015). Furthermore, using a randomized control cross-over
738 design, we recently demonstrated in-clinic improvements in clinical outcomes when the Walkasins
739 device was worn and turned on as compared to turned off (Koehler-McNicholas et al., 2019).
740 Consequently, we felt comfortable incorporating a single treatment arm design knowing the in-clinic
741 effects. Furthermore, any placebo effects were likely decreased by not systematically informing
742 subjects about any changes in outcomes and minimizing encouragement during interactions with
743 subjects that could affect expectation and beliefs in the treatment (Finniss et al., 2010; Enck et al.,
744 2013; Coste and Montel, 2017), and prohibiting any additional balance training/therapy intervention
745 during the 10 weeks of the trial.
746

747 If the effects in this study were placebo our findings should align with research findings on the
748 placebo arm of randomized, placebo-controlled trials (Wartolowska et al., 2016). A systematic
749 review of temporal changes in the placebo arm across 47 surgical randomized control trials found
750 that effects size of subjective outcomes was large (0.64), while effect size of objective clinical
751 outcomes was small (0.11) (Wartolowska et al., 2016). Furthermore, major differences in placebo-
752 effect sizes have been reported with subject-reported self-perception effects being larger than
753 observer-based ratings (Rief et al., 2009). On the contrary, effect sizes in the current study were large
754 for the clinical outcomes and small for the self-reported outcomes, supporting the interpretation that
755 effects were due to device use and not placebo. Further support of this view includes relatively high
756 subject compliance and reported device use and, a low subject dropout rate as well as the sustained
757 duration and continued gradual improvement in clinical outcomes throughout the 10-week period. An
758 additional weakness includes enrollment of mostly male subjects, partly due to nearly half of the
759 subjects being Veterans, who especially in this older generation are predominantly male. Strengths of
760 this trial include involvement of multiple sites across different geographies with different assessors at
761 different clinics limiting confounding balance interventions, and the use of standardized objective
762 clinical outcome measures.

763 5 Conclusion

764 A wearable sensory neuroprosthesis may provide a new way to treat gait and balance problems and
765 manage falls in high fall-risk patients with PN. Longer term data would be required to further
766 investigate actual decreases in falls.

767 6 Acknowledgments

768 We thank Lori Danzl, Alexandria Lloyd, Christine Olney (Minneapolis Department of Veterans
769 Affairs Health Care System, Minneapolis, MN), Tien Dat Nguyen, (M Health Fairview, Minneapolis,
770 MN), Nathan Silver (Baylor College of Medicine, Houston, TX), Ikechukwu Iloputaife, Wanting Yu
771 (Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Roslindale, MA) for
772 providing study coordination, subject recruitment and data gathering activities. We thank Annette
773 Xenopoulos-Oddsson (University of Minnesota, MN,), Dr. Lee Newcomer and Dr. Steven Stern for
774 reviewing drafts of the manuscript. The manuscript was published as a MedRxiv preprint (Oddsson
775 et al., 2020b).

776 7 Contribution to the Field Statement

777 Peripheral neuropathy is a condition affecting over 20 Million individuals in the US alone that causes
778 damage to nerves in the peripheral nervous system. Peripheral neuropathy is often related to diabetes,

Wearable Sensory Neuroprosthesis for Balance

779 chemotherapy treatment or has unknown causes. Symptoms of the disease that involve numbness and
780 loss of sensation in the feet often lead to problems with gait and balance and a high risk of falls. We
781 report results from the multi-site clinical trial, walk2Wellness, that has investigated long-term effects
782 of daily use of a new wearable sensory neuroprosthesis on gait function, balance, fall rates, and
783 quality of life in a group of peripheral neuropathy patients. The device (Walkasins®, RxFunction
784 Inc., MN, USA) provides directional tactile stimuli around the ankle during standing and walking
785 activities reflecting changes in foot pressure related to balance. Patients can then “feel” their feet in
786 contact with the ground, notice body sway during standing replacing their lost afferent nerve
787 function. Our results after 10 weeks of daily use show improved walking balance, speed of walking,
788 ability to rise from a chair move around and sit down and an encouraging trend in lower fall rates.
789 Also, participants with initial low self-confidence in their balance showed higher self-confidence.
790


Wearable Sensory Neuroprosthesis for Balance



791
792 **Figure 1.** Picture of the Walkasins sensory neuroprosthesis device showing the pressure sensor embedded Foot Pad that
793 is placed in the subject's shoe and connected to the Leg Unit that houses an embedded microprocessor with software,
794 supporting electronics, a rechargeable battery, and four tactile stimulators placed around the lower leg. The system is
795 worn bilaterally. Leg Unit and left Foot Pad shown

796
797
798

Wearable Sensory Neuroprosthesis for Balance



799
800
801

Figure 2. Flowchart of the study.

Wearable Sensory Neuroprosthesis for Balance

	n	Age (yrs)	Height (m)	Weight (kg)	#ChrD	FGA Score	Gait Speed Normal (m/s)	Gait Speed Fast (m/s)	TUG (s)	4-Stage Balance Test (s)
VAMC	20	74.7 (6.0)	1.76 (0.06)	96.9 (13.5)	9.8 (2.4)	14.8 (4.4)	0.80 (0.16)	1.2 (0.23)	14.7 (6.3)	25.0 (7.3)
Baylor	18	75.1 (11.7)	1.74 (0.08)	80.9 (18.1)	8.2 (3.0)	15.1 (4.2)	0.87 (0.25)	1.28 (0.39)	13.2 (5.2)	28.1 (8.2)
M Health Fairview	9	70.1 (7.8)	1.79 (0.12)	87.6 (10.5)	6.6 (4.1)	15.0 (3.2)	1.02 (0.28)	1.32 (0.27)	10.8 (2.3)	23.6 (5.2)
Harvard	5	78.2 (5.1)	1.71 (0.1)	95.0 (22.0)	5.2 (2.9)	14.0 (3.4)	0.77 (0.25)	1.07 (0.45)	15.0 (3.4)	28.3 (6.6)

802 **Table 1.** Baseline characteristics of subjects from the four different clinical sites enrolled in the study. Values represent
803 Mean (Standard Deviation). #ChrD - Number of Chronic Diseases.
804

Wearable Sensory Neuroprosthesis for Balance

Baseline Assessment	All n=52	Pre-F n=30	Pre-NF n=22	p-level
Gender Female (n)	11 of 52 (21%)	9 of 30 (30%)	2 of 22 (10%)	0.069
Use of Assistive Device (n)	28 of 52 (54%)	19 of 30 (63%)	9 of 22 (41%)	0.11
Gait Speed Normal <0.7m/s (n)	13 of 52 (25%)	10 of 30 (33%)	3 of 22 (14%)	0.10
Timed Up and Go >12s (n)	26 of 52 (50%)	18 of 30 (60%)	8 of 22 (36%)	0.09
4-Stage Balance Test <30s (n)	33 of 52 (63%)	22 of 30 (73%)	11 of 22 (50%)	0.08
ABC Score <67% (n)	30 of 52 (56%)	20 of 30 (67%)	10 of 22 (45%)	0.13
Fallen in Last 6 Months (n)	30 of 52 (58%)	30 of 30 (100%)	0	n/a
Fallen in Last 12 Months (n)	37 of 52 (71%)	30 of 30 (100%)	7 of 22 (32%)	<0.00001
Number of Falls 6 Months	65	65	0	n/a
Number of Falls 12 Months	121	109 of 121 (90%)	12 of 121 (10%)	<0.000001
	Mean (SD) n=52	Mean (SD) n=30	Mean (SD) n=22	p-level
Age (yrs)	74.4 (8.7)	73.8 (9.1)	75.2 (8.2)	0.57
Height (m)	1.75 (0.08)	1.76 (0.09)	1.75 (0.07)	0.54
Weight (kg)	89.6 (16.8)	89.7 (17.8)	89.3 (15.8)	0.93
BMI (kg/m ²)	29.1 (5.2)	29.0 (5.8)	29.2 (5.2)	0.92
FGA Score	14.9 (4.0)	13.5 (3.7)	16.7 (3.6)	<0.004
Gait Speed, Normal (m/s)	0.86 (0.23)	0.81 (0.26)	0.92 (0.18)	0.12
Gait Speed, Fast (m/s)	1.25 (0.37)	1.13 (0.34)	1.41 (0.35)	<0.006
TUG (s)	13.5 (5.3)	14.7 (6.3)	12.0 (2.9)	<0.05
4-Stage Balance Test (s)	26.2 (7.3)	24.8 (6.3)	28.0 (8.3)	0.055
Fall-Risk Factors* (n of 7)	4.5 (1.5)	5.3 (1.0)	3.5 (1.3)	<0.000001
ABC Score (%)	60.8 (17.6)	57.0 (15.2)	66.0 (19.7)	0.07
VADL Mean Score	3.66 (1.07)	3.94 (1.04)	3.29 (1.02)	<0.03
VAS Pain Score (0-10)	2.7 (2.2)	2.6 (2.1)	2.9 (2.4)	0.67
PHQ-9	4.4 (3.8)	5.2 (4.3)	3.4 (3.8)	0.11
Pain Interference PROMIS® 6b	51.1 (8.0)	52.5 (8.1)	49.0 (8.1)	0.10
Satisfaction Social Roles PROMIS® 8a	50.4 (7.8)	49.1 (7.7)	52.1 (7.8)	0.13
Ability to Participate PROMIS® 8a	50.0 (7.2)	49.8 (7.1)	50.2 (7.2)	0.88

805 **Table 2.** Baseline characteristics of subjects enrolled in the study (n=52), then separately for subjects who reported
 806 having fallen in the past six months (Pre-F) and those who did not (Pre-NF). Values shown are Mean (Standard
 807 Deviation). Column p-level shows significance level for comparison between the Pre-F and Pre-NF groups. In bold if
 808 p<0.05.

809 *Fall-risk factors assessed in the current study included, recent history of falls (Tinetti and Kumar, 2010), PN diagnosis
 810 (Richardson and Hurvitz, 1995), FGA score<23 (Wrisley and Kumar, 2010), TUG >12 s (CDC, 2017), 4-Stage Balance
 811 Test<30s (CDC, 2017), Gait Speed <0.7m/s (Studenski et al., 2003; Montero-Odasso et al., 2005), ABC score <67%
 812 (Lajoie and Gallagher, 2004).

813
 814

Wearable Sensory Neuroprosthesis for Balance

Baseline Assessment	All n=52	Pre-F n=30	Pre-NF n=22	p-level
Number of Chronic Conditions (n)	8.2 (3.3)	8.6 (3.2)	7.8 (3.4)	0.39
Peripheral Neuropathy (n)	52 (100%)	30 (100%)	22 (100%)	n/a
Numbness in Feet (n)	49 (94%)	30 (100%)	19 (86%)	<0.05
Neuropathic Pain in Feet (n)	38 (73%)	22 (73%)	16 (73%)	0.96
Hypertension (n)	33 (63%)	19 (63%)	14 (64%)	0.98
Back Pain (n)	26 (50%)	16 (53%)	10 (45%)	0.57
Arthritis (n)	24 (46%)	15 (50%)	9 (41%)	0.52
Knee Dysfunction (n)	23 (44%)	14 (47%)	9 (41%)	0.68
Diabetes Diagnosis (n)	19 (37%)	9 (30%)	10 (45%)	0.25
Inner Ear Problems (n)	17 (33%)	9 (30%)	8 (36%)	0.63
Heart Disease (n)	16 (31%)	10 (33%)	6 (27%)	0.64
Neck Pain (n)	16 (31%)	9 (30%)	7 (32%)	0.89
Cancer (n)	16 (31%)	13 (43%)	3 (14%)	<0.03
Lung Disease (n)	10 (19%)	7 (23%)	3 (14%)	0.38
Stroke (n)	9 (17%)	4 (13%)	5 (23%)	0.38
Osteoporosis(n)	10 (19%)	7 (23%)	3 (14%)	0.38
Seizures (n)	5 (10%)	3 (10%)	2 (9%)	0.91
Ankle Dysfunction (n)	5 (10%)	4 (13%)	1 (5%)	0.29
TMJ/Jaw Pain (n)	5 (10%)	2 (7%)	3 (14%)	0.40
Fainting (n)	5 (10%)	2 (7%)	3 (14%)	0.40
Migraines (n)	4 (8%)	2 (7%)	2 (9%)	0.75
Meningitis (n)	0	0	0	n/a
Other Conditions (n)	14 (27%)	11 (37%)	3 (14%)	0.06
Difficulty Walking/balance (n)	52 (100%)	30 (100%)	22 (100%)	n/a
	Mean (SD) Median	Mean (SD)	Mean (SD)	p-level
Prescription Medications (n)	8	8.5	7	0.50
Non-Prescription Medications (n)	1	1	1	n/a
Medications Associated with Falls (n)	3	3	3	n/a

Table 3. Self-reported chronic conditions as well as medication use for subjects enrolled in the study. Column p-level shows significance level for comparison between the Pre-F and Pre-NF groups. In bold if p<0.05.

815
816
817
818

Wearable Sensory Neuroprosthesis for Balance

ALL	Baseline Mean (SD) <i>n=45</i>	2-week Mean (SD) <i>n=45</i>	6-week Mean (SD) <i>n=45</i>	10-week Mean (SD) <i>n=45</i>	ANOVA p-level	Cohen's d (95% CI's)
FGA Score	15.0 (4.0)	18.3 (4.4) <0.0000001	18.5(4.4) <0.0000001	19.1 (5.2) <0.0000001	<0.00001	0.92 (0.49, 1.35)
Gait Speed Normal (m/s)	0.86 (0.24)	0.92 (0.26) <0.002	0.94 (0.25) <0.0001	0.95 (0.24) <0.00005	<0.00001	0.42 (0.01, 0.82)
Gait Speed Fast (m/s)	1.24 (0.37)	1.27 (0.33) 0.30	1.30 (0.37) <0.016	1.33 (0.38) <0.00168	<0.013	0.27 (-0.14, 0.67)
TUG (s)	13.8 (5.5)	12.7 (4.2) 0.06	12.3 (4.2) <0.034 (0.69) 0.0397*	12.5 (3.7) <0.012	<0.01	0.28 (-0.12, 0.68)
4-Stage Balance Test (s)	26.2 (7.1)	27.1 (7.7)	27.7 (7.7)	27.8 (6.8)	0.23	n/a
Pre-Fallers	Baseline Mean (SD) <i>n=25</i>	2-week Mean (SD) <i>n=25</i>	6-week Mean (SD) <i>n=25</i>	10-week Mean (SD) <i>n=25</i>	p-level ANOVA	Cohen's d (95% CI's)
FGA Score	13.5 (3.6)	16.6 (3.7) <0.0000005	17.3 (4.1) <0.00002	16.8 (4.9) <0.00016	<0.00001	0.82 (0.26, 1.39)
Gait Speed Normal (m/s)	0.79 (0.27)	0.85 (0.26) <0.022 (0.90) 0.047*	0.89 (0.25) <0.0021	0.86 (0.24) <0.016	<0.0014	0.28 (-0.27, 0.83)
Gait Speed Fast (m/s)	1.09 (0.33)	1.16 (0.30) <0.035 (0.88) 0.046*	1.17 (0.32) <0.0165	1.17 (0.35) <0.015	<0.028	0.27 (-0.28, 0.82)
TUG (s)	15.3 (6.6)	14.0 (4.6) 0.14	13.3 (3.8) 0.047	13.7 (4.2) 0.056	<0.025	n/a
4-Stage Balance Test (s)	24.7 (5.5)	25.4 (7.8)	26.0 (7.9)	27.5 (6.1)	0.15	n/a
Pre-NonFallers	Baseline Mean (SD) <i>n=20</i>	2-week Mean (SD) <i>n=20</i>	6-week Mean (SD) <i>n=20</i>	10-week Mean (SD) <i>n=20</i>	p-level ANOVA	Cohen's d (95% CI's)
FGA Score	16.9 (3.6)	20.5 (4.4) <0.00009	20.1 (4.3) <0.00004	22.0 (4.0) <0.00004	<0.0000001	1.38 (0.70, 2.1)
Gait Speed Normal (m/s)	0.93 (0.17)	1.01 (0.22) <0.031 (0.78) 0.043*	1.01 (0.24) <0.019 (0.84) 0.045*	1.06 (0.20) <0.0004	<0.0011	0.74 (0.10, 1.37)
Gait Speed Fast (m/s)	1.41 (0.35)	1.42 (0.33)	1.43 (0.41)	1.52 (0.34)	0.10	n/a
TUG (s)	11.9 (2.9)	11.2 (3.2)	11.7 (5.0)	10.9 (2.2)	0.49	n/a
4-Stage Balance Test (s)	27.6 (8.5)	29.4 (7.1)	29.9 (7.1)	28.1 (7.7)	0.45	n/a

819 **Table 4.** Clinical outcomes for the 45 subjects completing all assessments for baseline, 2, 6 and 10 weeks as well as the
820 subgroups of Pre-Fallers and Pre-NonFallers. Values in **bold** indicate statistical significance. ANOVA column shows
821 significance levels of main effect from initial repeated measures ANOVA test. If significant ($p<0.05$), pairwise
822 comparisons were made using three dependent t-tests between baseline and 2, 6 and 10-week assessments, respectively.
823 Bonferroni's adjustment of significance levels for correlated measures was applied. As noted, values in *(italics)* indicate
824 Pearson's correlation coefficient followed by the adjusted significance level required for an overall significance of 0.05 as
825 marked with *. If ANOVA was non-significant, no further comparisons were made. Cohen's d indicates effect size where
826 0.2 is represents a small effect, 0.5 a medium effect, and 0.8 a large effect. Values in parenthesis show 95% confidence
827 interval.

828

Wearable Sensory Neuroprosthesis for Balance

ALL (n=45)	Baseline Mean (SD) n=45	2-week Mean (SD) n=45	6-week Mean (SD) n=45	10-week Mean (SD) n=45	ANOVA p-level
ABC-Score (%)	61.4 (17.9)	65.0 (13.1)	64.2 (15.1)	65.1 (14.1)	0.36
VADL Mean Score	3.70 (1.09) 0.053	3.37 (0.86) 0.16	3.52 (0.99) 0.99	3.63 (0.93)	<0.044
VAS Score (0-10)	2.8 (2.2)	2.5 (2.1)	2.5 (2.2)	2.6 (2.3)	0.31
PHQ-9	4.5 (3.9)	3.8 (3.5)	3.6 (3.8)	3.9 (4.5)	0.25
Pain Interference PROMIS® 6b	50.8 (7.9)	51.2 (8.1)	50.5 (8.9)	51.8 (8.5)	0.85
Satisfaction Social Roles PROMIS® 8a	50.2 (7.8)	52.1 (7.2)	51.7 (7.3)	52.1 (7.8)	0.10
Ability to Participate PROMIS® 8a	49.8 (7.3)	50.7 (6.4)	51.0 (7.1)	51.3 (8.1)	0.38
R 1st MTP Joint	2.0 (2.5)	n/a	n/a	2.0 (2.5)	n/a
R Lateral Malleolus	3.6 (2.7)	n/a	n/a	3.4 (2.6)	n/a
R Patella	4.5 (2.0)	n/a	n/a	4.5 (1.8)	n/a
L 1st MTP Joint	2.3 (2.6)	n/a	n/a	2.2 (2.7)	n/a
L Lateral Malleolus	3.7 (2.7)	n/a	n/a	3.6 (2.5)	n/a
L Patella	4.3 (2.1)	n/a	n/a	4.4 (1.6)	n/a
Pre-Fallers (n=25)	Baseline Mean (SD)	2-week Mean (SD)	6-week Mean (SD)	10-week Mean (SD)	p-level
ABC-Score (%)	57.7 (17.9)	61.5 (14.0)	61.8 (15.1)	61.2 (13.9)	0.29
VADL Mean Score	4.00 (1.13)	3.68 (0.90)	3.83 (1.01)	3.91 (0.97)	0.42
VAS Score (0-10)	2.5 (2.4)	2.5 (2.5)	2.8 (2.6)	2.6 (2.5)	0.55
PHQ-9	5.3 (3.9)	4.7 (3.3)	3.9 (3.3)	4.5. (3.5)	0.08
Pain Interference PROMIS® 6b	51.9 (8.3)	52.2 (8.5)	51.6 (9.9)	53.6 (8.0)	0.90
Satisfaction Social Roles PROMIS® 8a	49.1 (8.0)	49.9 (7.9)	49.2 (7.5)	49.6 (7.7)	0.68
Ability to Participate PROMIS® 8a	49.9 (7.5)	48.6 (5.8)	49.5 (6.8)	49.4 8.0)	0.58
Pre-NonFallers (n=20)	Baseline Mean (SD)	2-week Mean (SD)	6-week Mean (SD)	10-week Mean (SD)	p-level
ABC-Score (%)	66.2 (18.0)	69.8 (11.9)	67.2 (15.1)	70.2 (14.6)	0.96
VADL Mean Score	3.32 (1.06)	2.94 (0.80)	3.11 (0.99)	3.28 (0.89)	0.08
VAS Score (0-10)	3.0 (2.0)	2.4 (1.5)	2.2 (1.7)	2.7 (2.0)	0.10
PHQ-9	3.5 (3.9)	2.6.(3.7)	3.2 (4.4)	3.2 (5.6)	0.66
Pain Interference PROMIS® 6b	49.4 (7.6)	49.8 (7.6)	49.1 (7.6)	49.3 (9.1)	0.91
Satisfaction Social Roles PROMIS® 8a	51.7 (7.8)	55 .1 (6.4)	54.8 (7.0)	55.4 (8.0)	0.12
Ability to Participate PROMIS® 8a	49.7 (7.1)	53.7 (7.3) <0.02 (0.64) 0.038*	52.8 (7.6) 0.06	53.7 (8.4) 0.05	<0.041

829
830 **Table 5.** Results from participant-reported outcomes and Rydel-Seiffer vibration sensation screening for the 45 subjects
831 who completed all assessments. Data is shown separately for the group as a whole and for Pre-Fallers (having reported
832 fallen in the previous 6 months) and Pre-NonFallers (no falls reported in the previous 6 months). Values in (*italics*)
833 indicate Pearson's correlation coefficient followed by the Bonferroni adjusted significance level required for an overall
834 significance of 0.05 as marked with *. There were no differences in vibration sensation between Pre-Fallers and Pre-
835 NonFallers and no differences between baseline and 10-week assessments.


835

Wearable Sensory Neuroprosthesis for Balance

All (n=45)	Baseline	10 Weeks	p-level
Number of Subjects FGA>22	0 of 45	13 of 45	n/a
#Falls (pre-6 mo & in study)	62	17	n/a
Fall Rate (pre-6mo & in study)	7.7	5.4	0.27*
#Fallers (pre-6mo & in study)	25	22	n/a
# Fall Risk Factors	4.2 (1.5)	3.8 (1.6)	<0.047
Pre-Fallers (n=25)			
Number of Subjects FGA>22	0 of 25	4 of 25	n/a
#Falls (pre-6 mo & in study)	62	13	n/a
Fall Rate (pre-6mo & in study)	13.8	7.4	<0.014*
#Fallers (pre-6mo & in study)	25	9	n/a
# Fall Risk Factors	5.1 (1.3)	4.3 (1.7)	<0.023
Pre-NonFallers (n=20)			
Number of Subjects FGA>22	0 of 20	9 of 20	n/a
#Falls (pre-6 mo & in study)	0	4	n/a
Fall Rate (pre-6mo & in study)	0	2.9	0.125*
#Fallers (pre-6mo & in study)	0	4	n/a
# Fall Risk Factors	3.2 (1.8)	3.1 (1.7)	0.76

836 **Table 6.** Parameters related to falls and fall risk assessed at baseline and at 10 weeks. Fall rates are reported in number of
837 falls per 1000 patient days. Fall risk factors are identified in Table 2. *Wilcoxon Signed Rank test
838

Wearable Sensory Neuroprosthesis for Balance



839
840

841 **Figure 3.** Graphs showing baseline vs. 10-week FGA (A) and ABC scores (B). Markers above line of identity indicate
842 higher scores at 10-week assessment. Notice line of regression for FGA scores is near parallel to line of identity
843 indicating a similar increase across all baseline FGA scores. For ABC scores the line of regression intersects the line of
844 identify near 67% indicating an increase for lower baseline ABC scores and a decrease for higher baseline ABC scores.

845
846

Wearable Sensory Neuroprosthesis for Balance

847

8 References

- 848 Akbari, M., Jafari, H., Moshashaee, A., and Forough, B. (2012). Do diabetic neuropathy patients
849 benefit from balance training? *J Rehabil Res Dev* 49(2), 333-338. doi:
850 10.1682/jrrd.2010.10.0197.
- 851 Alfonso-Rosa, R.M., Del Pozo-Cruz, B., Del Pozo-Cruz, J., Sañudo, B., and Rogers, M.E. (2014).
852 Test-retest reliability and minimal detectable change scores for fitness assessment in older
853 adults with type 2 diabetes. *Rehabil Nurs* 39(5), 260-268. doi: 10.1002/rnj.111.
- 854 Algina, J., Keselman, H.J., and Penfield, R.D. (2005). Effect Sizes and their Intervals: The Two-Level
855 Repeated Measures Case. *Edu Psych Meas* 65(April), 241–258. doi:
856 10.1177/0013164404268675.
- 857 Allet, L., Armand, S., de Bie, R.A., Golay, A., Monnin, D., Aminian, K., et al. (2010). The gait and
858 balance of patients with diabetes can be improved: a randomised controlled trial.
859 *Diabetologia* 53(3), 458-466. doi: 10.1007/s00125-009-1592-4.
- 860 Askew, R.L., Cook, K.F., Revicki, D.A., Cella, D., and Amtmann, D. (2016). Evidence from diverse
861 clinical populations supported clinical validity of PROMIS pain interference and pain
862 behavior. *J Clin Epidemiol* 73, 103-111. doi: 10.1016/j.jclinepi.2015.08.035.
- 863 Bach-y-Rita, P. (2004). Tactile sensory substitution studies. *Ann N Y Acad Sci* 1013, 83-91.
- 864 Bach-y-Rita, P., Collins, C.C., Saunders, F.A., White, B., and Scadden, L. (1969). Vision substitution
865 by tactile image projection. *Trans Pac Coast Otoophthalmol Soc Annu Meet* 50, 83-91.
- 866 Badke, M.B., Sherman, J., Boyne, P., Page, S., and Dunning, K. (2011). Tongue-based biofeedback
867 for balance in stroke: results of an 8-week pilot study. *Arch Phys Med Rehabil* 92(9), 1364-
868 1370. doi: 10.1016/j.apmr.2011.03.030.
- 869 Bao, T., Carender, W.J., Kinnaird, C., Barone, V.J., Peethambaran, G., Whitney, S.L., et al. (2018).
870 Effects of long-term balance training with vibrotactile sensory augmentation among
871 community-dwelling healthy older adults: a randomized preliminary study. *J Neuroeng
872 Rehabil* 15(1), 5. doi: 10.1186/s12984-017-0339-6.
- 873 Basta, D., Rossi-Izquierdo, M., Soto-Varela, A., Greters, M.E., Bittar, R.S., Steinhagen-Thiessen, E.,
874 et al. (2011). Efficacy of a vibrotactile neurofeedback training in stance and gait conditions
875 for the treatment of balance deficits: a double-blind, placebo-controlled multicenter study.
876 *Otol Neurotol* 32(9), 1492-1499. doi: 10.1097/MAO.0b013e31823827ec.
- 877 Beninato, M., Fernandes, A., and Plummer, L.S. (2014). Minimal clinically important difference of
878 the functional gait assessment in older adults. *Phys Ther* 94(11), 1594-1603. doi:
879 10.2522/ptj.20130596.
- 880 Bent, L.R., Inglis, J.T., and McFadyen, B.J. (2004). When is vestibular information important during
881 walking? *J Neurophysiol* 92(3), 1269-1275. doi: 10.1152/jn.01260.2003.
- 882 Bergen, G., Stevens, M.R., and Burns, E.R. (2016). Falls and Fall Injuries Among Adults Aged ≥65
883 Years - United States, 2014. *MMWR Morb Mortal Wkly Rep* 65(37), 993-998. doi:
884 10.15585/mmwr.mm6537a2.
- 885 Bischoff, H.A., Stähelin, H.B., Monsch, A.U., Iversen, M.D., Weyh, A., von Dechend, M., et al.
886 (2003). Identifying a cut-off point for normal mobility: a comparison of the timed 'up and go'
887 test in community-dwelling and institutionalised elderly women. *Age Ageing* 32(3), 315-320.
888 doi: 10.1093/ageing/32.3.315.
- 889 Bronstein, A.M. (1999). The interaction of otolith and proprioceptive information in the perception
890 of verticality. The effects of labyrinthine and CNS disease. *Ann N Y Acad Sci* 871, 324-333.
891 doi: 10.1111/j.1749-6632.1999.tb09195.x.

Wearable Sensory Neuroprosthesis for Balance

- 892 Bulat, T., Hart-Hughes, S., Ahmed, S., Quigley, P., Palacios, P., Werner, D.C., et al. (2007). Effect of
893 a group-based exercise program on balance in elderly. *Clin Interv Aging* 2(4), 655-660. doi:
894 10.2147/cia.s204.
- 895 Buracchio, T., Dodge, H.H., Howieson, D., Wasserman, D., and Kaye, J. (2010). The trajectory of
896 gait speed preceding mild cognitive impairment. *Arch Neurol* 67(8), 980-986. doi:
897 10.1001/archneurol.2010.159.
- 898 Cakrt, O., Vyhálek, M., Slabý, K., Funda, T., Vuillerme, N., Kolář, P., et al. (2012). Balance
899 rehabilitation therapy by tongue electrotactile biofeedback in patients with degenerative
900 cerebellar disease. *NeuroRehabilitation* 31(4), 429-434. doi: 10.3233/NRE-2012-00813.
- 901 Cavanagh, P.R., Derr, J.A., Ulbrecht, J.S., Maser, R.E., and Orchard, T.J. (1992). Problems with gait
902 and posture in neuropathic patients with insulin-dependent diabetes mellitus. *Diabet Med*
903 9(5), 469-474. doi: 10.1111/j.1464-5491.1992.tb01819.x.
- 904 CDC (2017). *STEADI - Older Adult Fall Prevention* [Online]. On line: Centers for Disease Control
905 and Prevention. Available: <https://www.cdc.gov/steady/materials.html> [Accessed May 5, 2018
906 2018].
- 907 Chodzko-Zajko, W.J., Proctor, D.N., Fiatarone Singh, M.A., Minson, C.T., Nigg, C.R., Salem, G.J.,
908 et al. (2009). American College of Sports Medicine position stand. Exercise and physical
909 activity for older adults. *Med Sci Sports Exerc* 41(7), 1510-1530. doi:
910 10.1249/MSS.0b013e3181a0c95c.
- 911 Cohen, H.S., Kimball, K.T., and Adams, A.S. (2000). Application of the vestibular disorders
912 activities of daily living scale. *Laryngoscope* 110(7), 1204-1209. doi: 10.1097/00005537-
913 200007000-00026.
- 914 Cohen, J. (1988). *Statistical Power Analysis for the Behavioral Sciences*. New York, NY: Routledge
915 Academic.
- 916 Coste, J., and Montel, S. (2017). Placebo-related effects: a meta-narrative review of
917 conceptualization, mechanisms and their relevance in rheumatology. *Rheumatology (Oxford)*
918 56(3), 334-343. doi: 10.1093/rheumatology/kew274.
- 919 Cyarto, E.V., Brown, W.J., Marshall, A.L., and Trost, S.G. (2008). Comparative effects of home- and
920 group-based exercise on balance confidence and balance ability in older adults: cluster
921 randomized trial. *Gerontology* 54(5), 272-280. doi: 10.1159/000155653.
- 922 DeMott, T.K., Richardson, J.K., Thies, S.B., and Ashton-Miller, J.A. (2007). Falls and gait
923 characteristics among older persons with peripheral neuropathy. *Am J Phys Med Rehabil*
924 86(2), 125-132. doi: 10.1097/PHM.0b013e31802ee1d1.
- 925 Dingwell, J.B., Cusumano, J.P., Sternad, D., and Cavanagh, P.R. (2000). Slower speeds in patients
926 with diabetic neuropathy lead to improved local dynamic stability of continuous overground
927 walking. *J Biomech* 33(10), 1269-1277. doi: 10.1016/s0021-9290(00)00092-0.
- 928 Dixon, C.J., Knight, T., Binns, E., Ihaka, B., and O'Brien, D. (2017). Clinical measures of balance in
929 people with type two diabetes: A systematic literature review. *Gait Posture* 58, 325-332. doi:
930 10.1016/j.gaitpost.2017.08.022.
- 931 Enck, P., Bingel, U., Schedlowski, M., and Rief, W. (2013). The placebo response in medicine:
932 minimize, maximize or personalize? *Nat Rev Drug Discov* 12(3), 191-204. doi:
933 10.1038/nrd3923.
- 934 Finniss, D.G., Kaptchuk, T.J., Miller, F., and Benedetti, F. (2010). Biological, clinical, and ethical
935 advances of placebo effects. *Lancet* 375(9715), 686-695. doi: 10.1016/S0140-6736(09)61706-
936 2.
- 937 Florence, C.S., Bergen, G., Atherly, A., Burns, E., Stevens, J., and Drake, C. (2018). Medical Costs
938 of Fatal and Nonfatal Falls in Older Adults. *J Am Geriatr Soc* 66(4), 693-698. doi:
939 10.1111/jgs.15304.

Wearable Sensory Neuroprosthesis for Balance

- 940 Ganz, D.A., Bao, Y., Shekelle, P.G., and Rubenstein, L.Z. (2007). Will my patient fall? *JAMA*
941 297(1), 77-86. doi: 10.1001/jama.297.1.77.
- 942 Ganz, D.A., and Latham, N.K. (2020). Prevention of Falls in Community-Dwelling Older Adults. *N
943 Engl J Med* 382(8), 734-743. doi: 10.1056/NEJMcp1903252.
- 944 Gregg, E.W., Sorlie, P., Paulose-Ram, R., Gu, Q., Eberhardt, M.S., Wolz, M., et al. (2004).
945 Prevalence of lower-extremity disease in the US adult population ≥ 40 years of age with and
946 without diabetes: 1999-2000 national health and nutrition examination survey. *Diabetes Care*
947 27(7), 1591-1597. doi: 10.2337/diacare.27.7.1591.
- 948 Guertin, P.A. (2012). Central pattern generator for locomotion: anatomical, physiological, and
949 pathophysiological considerations. *Front Neurol* 3, 183. doi: 10.3389/fneur.2012.00183.
- 950 Hahn, E.A., Beaumont, J.L., Pilkonis, P.A., Garcia, S.F., Magasi, S., DeWalt, D.A., et al. (2016a).
951 The PROMIS satisfaction with social participation measures demonstrated responsiveness in
952 diverse clinical populations. *J Clin Epidemiol* 73, 135-141. doi:
953 10.1016/j.jclinepi.2015.08.034.
- 954 Hahn, E.A., DeWalt, D.A., Bode, R.K., Garcia, S.F., DeVellis, R.F., Correia, H., et al. (2014). New
955 English and Spanish social health measures will facilitate evaluating health determinants.
956 *Health Psychol* 33(5), 490-499. doi: 10.1037/head0000055.
- 957 Hahn, E.A., Kallen, M.A., Jensen, R.E., Potosky, A.L., Moinpour, C.M., Ramirez, M., et al. (2016b).
958 Measuring social function in diverse cancer populations: Evaluation of measurement
959 equivalence of the Patient Reported Outcomes Measurement Information System. *Psychol
960 Test Assess Model* 58(2), 403-421.
- 961 Halvarsson, A., Franzén, E., Farén, E., Olsson, E., Oddsson, L., and Ståhle, A. (2013). Long-term
962 effects of new progressive group balance training for elderly people with increased risk of
963 falling - a randomized controlled trial. *Clin Rehabil* 27(5), 450-458. doi:
964 10.1177/0269215512462908.
- 965 Halvarsson, A., Oddsson, L., Olsson, E., Farén, E., Pettersson, A., and Ståhle, A. (2011). Effects of
966 new, individually adjusted, progressive balance group training for elderly people with fear of
967 falling and tend to fall: a randomized controlled trial. *Clin Rehabil* 25(11), 1021-1031. doi:
968 10.1177/0269215511411937.
- 969 Hanewinkel, R., Drenthen, J., Verlinden, V.J.A., Darweesh, S.K.L., van der Geest, J.N., Hofman,
970 A., et al. (2017). Polyneuropathy relates to impairment in daily activities, worse gait, and fall-
971 related injuries. *Neurology* 89(1), 76-83. doi: 10.1212/WNL.0000000000004067.
- 972 Hannan, M.T., Gagnon, M.M., Aneja, J., Jones, R.N., Cupples, L.A., Lipsitz, L.A., et al. (2010).
973 Optimizing the tracking of falls in studies of older participants: comparison of quarterly
974 telephone recall with monthly falls calendars in the MOBILIZE Boston Study. *Am J
975 Epidemiol* 171(9), 1031-1036. doi: 10.1093/aje/kwq024.
- 976 Hardy, S.E., Perera, S., Roumani, Y.F., Chandler, J.M., and Studenski, S.A. (2007). Improvement in
977 usual gait speed predicts better survival in older adults. *J Am Geriatr Soc* 55(11), 1727-1734.
978 doi: 10.1111/j.1532-5415.2007.01413.x.
- 979 Hegeman, J., Honegger, F., Kupper, M., and Allum, J.H. (2005). The balance control of bilateral
980 peripheral vestibular loss subjects and its improvement with auditory prosthetic feedback. *J
981 Vestib Res* 15(2), 109-117.
- 982 Hiengkaew, V., Jitaree, K., and Chaiyawat, P. (2012). Minimal detectable changes of the Berg
983 Balance Scale, Fugl-Meyer Assessment Scale, Timed "Up & Go" Test, gait speeds, and 2-
984 minute walk test in individuals with chronic stroke with different degrees of ankle
985 plantarflexor tone. *Arch Phys Med Rehabil* 93(7), 1201-1208. doi:
986 10.1016/j.apmr.2012.01.014.

Wearable Sensory Neuroprosthesis for Balance

- 987 Hlavacka, F., Krizková, M., and Horak, F.B. (1995). Modification of human postural response to leg
988 muscle vibration by electrical vestibular stimulation. *Neurosci Lett* 189(1), 9-12. doi:
989 10.1016/0304-3940(95)11436-z.
- 990 Hoffman, E.M., Staff, N.P., Robb, J.M., St Sauver, J.L., Dyck, P.J., and Klein, C.J. (2015).
991 Impairments and comorbidities of polyneuropathy revealed by population-based analyses.
992 *Neurology* 84(16), 1644-1651. doi: 10.1212/WNL.0000000000001492.
- 993 Ites, K.I., Anderson, E.J., Cahill, M.L., Kearney, J.A., Post, E.C., and Gilchrist, L.S. (2011). Balance
994 interventions for diabetic peripheral neuropathy: a systematic review. *J Geriatr Phys Ther*
995 34(3), 109-116. doi: 10.1519/JPT.0b013e318212659a.
- 996 Jónsdóttir, H.L., and Ruthig, J.C. (2020). A longitudinal study of the negative impact of falls on
997 health, well-being, and survival in later life: the protective role of perceived control. *Aging*
998 *Ment Health*, 1-7. doi: 10.1080/13607863.2020.1725736.
- 999 Kim, D.H., Glynn, R.J., Avorn, J., Lipsitz, L.A., Rockwood, K., Pawar, A., et al. (2019). Validation
1000 of a Claims-Based Frailty Index Against Physical Performance and Adverse Health Outcomes
1001 in the Health and Retirement Study. *J Gerontol A Biol Sci Med Sci* 74(8), 1271-1276. doi:
1002 10.1093/gerona/gly197.
- 1003 Koehler-McNicholas, S.R., Danzl, L., Cataldo, A.Y., and Oddsson, L.I.E. (2019). Neuromodulation
1004 to improve gait and balance function using a sensory neuroprosthesis in people who report
1005 insensate feet - A randomized control cross-over study. *PLoS One* 14(4), e0216212. doi:
1006 10.1371/journal.pone.0216212.
- 1007 Kroenke, K., Spitzer, R.L., and Williams, J.B. (2001). The PHQ-9: validity of a brief depression
1008 severity measure. *J Gen Intern Med* 16(9), 606-613. doi: 10.1046/j.1525-
1009 1497.2001.016009606.x.
- 1010 Kruse, R.L., Lemaster, J.W., and Madsen, R.W. (2010). Fall and balance outcomes after an
1011 intervention to promote leg strength, balance, and walking in people with diabetic peripheral
1012 neuropathy: "feet first" randomized controlled trial. *Phys Ther* 90(11), 1568-1579. doi:
1013 10.2522/ptj.20090362.
- 1014 Kästenbauer, T., Sauseng, S., Brath, H., Abrahamian, H., and Irsigler, K. (2004). The value of the
1015 Rydel-Seiffer tuning fork as a predictor of diabetic polyneuropathy compared with a
1016 neurothesiometer. *Diabet Med* 21(6), 563-567. doi: 10.1111/j.1464-5491.2004.01205.x.
- 1017 Lajoie, Y., and Gallagher, S.P. (2004). Predicting falls within the elderly community: comparison of
1018 postural sway, reaction time, the Berg balance scale and the Activities-specific Balance
1019 Confidence (ABC) scale for comparing fallers and non-fallers. *Arch Gerontol Geriatr* 38(1),
1020 11-26.
- 1021 Lakens, D. (2013). Calculating and reporting effect sizes to facilitate cumulative science: a practical
1022 primer for t-tests and ANOVAs. *Front Psychol* 4, 863. doi: 10.3389/fpsyg.2013.00863.
- 1023 Lawrence, R.H., Tennstedt, S.L., Kasten, L.E., Shih, J., Howland, J., and Jette, A.M. (1998).
1024 Intensity and correlates of fear of falling and hurting oneself in the next year: baseline
1025 findings from a Roybal Center fear of falling intervention. *J Aging Health* 10(3), 267-286.
1026 doi: 10.1177/089826439801000301.
- 1027 Leddy, A.L., Crowner, B.E., and Earhart, G.M. (2011). Functional gait assessment and balance
1028 evaluation system test: reliability, validity, sensitivity, and specificity for identifying
1029 individuals with Parkinson disease who fall. *Phys Ther* 91(1), 102-113. doi:
1030 10.2522/ptj.20100113.
- 1031 Lee, B.C., Thrasher, T.A., Fisher, S.P., and Layne, C.S. (2015). The effects of different sensory
1032 augmentation on weight-shifting balance exercises in Parkinson's disease and healthy elderly
1033 people: a proof-of-concept study. *J Neuroeng Rehabil* 12, 75. doi: 10.1186/s12984-015-0064-
1034 y.

Wearable Sensory Neuroprosthesis for Balance

- 1035 Leonard, G., Lapierre, Y., Chen, J.K., Wardini, R., Crane, J., and Ptito, A. (2017). Noninvasive
1036 tongue stimulation combined with intensive cognitive and physical rehabilitation induces
1037 neuroplastic changes in patients with multiple sclerosis: A multimodal neuroimaging study.
1038 *Mult Scler J Exp Transl Clin* 3(1), 2055217317690561. doi: 10.1177/2055217317690561.
- 1039 Li, F., Harmer, P., Fisher, K.J., and McAuley, E. (2004). Tai Chi: improving functional balance and
1040 predicting subsequent falls in older persons. *Med Sci Sports Exerc* 36(12), 2046-2052.
- 1041 Li, F., Harmer, P., Fisher, K.J., McAuley, E., Chaumeton, N., Eckstrom, E., et al. (2005). Tai Chi and
1042 fall reductions in older adults: a randomized controlled trial. *J Gerontol A Biol Sci Med Sci*
1043 60(2), 187-194. doi: 10.1093/gerona/60.2.187.
- 1044 Li, L., and Manor, B. (2010). Long term Tai Chi exercise improves physical performance among
1045 people with peripheral neuropathy. *Am J Chin Med* 38(3), 449-459. doi:
1046 10.1142/S0192415X1000797X.
- 1047 Lin, J.H., Hsu, M.J., Hsu, H.W., Wu, H.C., and Hsieh, C.L. (2010). Psychometric comparisons of 3
1048 functional ambulation measures for patients with stroke. *Stroke* 41(9), 2021-2025. doi:
1049 10.1161/STROKEAHA.110.589739.
- 1050 Lipsitz, L.A., Lough, M., Niemi, J., Travison, T., Howlett, H., and Manor, B. (2015). A shoe insole
1051 delivering subsensory vibratory noise improves balance and gait in healthy elderly people.
1052 *Arch Phys Med Rehabil* 96(3), 432-439. doi: 10.1016/j.apmr.2014.10.004.
- 1053 Lipsitz, L.A., Macklin, E.A., Travison, T.G., Manor, B., Gagnon, P., Tsai, T., et al. (2019). A Cluster
1054 Randomized Trial of Tai Chi vs Health Education in Subsidized Housing: The MI-WiSH
1055 Study. *J Am Geriatr Soc* 67(9), 1812-1819. doi: 10.1111/jgs.15986.
- 1056 Lipsitz, L.A., Manor, B., Habtemariam, D., Ilopputaife, I., Zhou, J., and Travison, T.G. (2018). The
1057 pace and prognosis of peripheral sensory loss in advanced age: association with gait speed
1058 and falls. *BMC Geriatr* 18(1), 274. doi: 10.1186/s12877-018-0970-5.
- 1059 Manor, B., Lough, M., Gagnon, M.M., Cupples, A., Wayne, P.M., and Lipsitz, L.A. (2014).
1060 Functional benefits of tai chi training in senior housing facilities. *J Am Geriatr Soc* 62(8),
1061 1484-1489. doi: 10.1111/jgs.12946.
- 1062 Marsden, J.F., Blakey, G., and Day, B.L. (2003). Modulation of human vestibular-evoked postural
1063 responses by alterations in load. *J Physiol* 548(Pt 3), 949-953. doi:
1064 10.1113/jphysiol.2002.029991.
- 1065 Mathias, S., Nayak, U.S., and Isaacs, B. (1986). Balance in elderly patients: the "get-up and go" test.
1066 *Arch Phys Med Rehabil* 67(6), 387-389.
- 1067 Melzer, I., and Oddsson, L.I.e. (2013). Improving balance control and self-reported lower extremity
1068 function in community-dwelling older adults: a randomized control trial. *Clin Rehabil* 27(3),
1069 195-206. doi: 10.1177/0269215512450295.
- 1070 Menz, H.B., Lord, S.R., St George, R., and Fitzpatrick, R.C. (2004). Walking stability and
1071 sensorimotor function in older people with diabetic peripheral neuropathy. *Arch Phys Med
1072 Rehabil* 85(2), 245-252. doi: 10.1016/j.apmr.2003.06.015.
- 1073 Meyer, P.F., Oddsson, L.I., and De Luca, C.J. (2004a). Reduced plantar sensitivity alters postural
1074 responses to lateral perturbations of balance. *Exp Brain Res* 157(4), 526-536. doi:
1075 10.1007/s00221-004-1868-3.
- 1076 Meyer, P.F., Oddsson, L.I., and De Luca, C.J. (2004b). The role of plantar cutaneous sensation in
1077 unperturbed stance. *Exp Brain Res* 156(4), 505-512. doi: 10.1007/s00221-003-1804-y.
- 1078 Middleton, A., Fritz, S.L., and Lusardi, M. (2015). Walking speed: the functional vital sign. *J Aging
1079 Phys Act* 23(2), 314-322. doi: 10.1123/japa.2013-0236.
- 1080 Montero-Odasso, M., Schapira, M., Soriano, E.R., Varela, M., Kaplan, R., Camera, L.A., et al.
1081 (2005). Gait velocity as a single predictor of adverse events in healthy seniors aged 75 years
1082 and older. *J Gerontol A Biol Sci Med Sci* 60(10), 1304-1309. doi: 10.1093/gerona/60.10.1304.

Wearable Sensory Neuroprosthesis for Balance

- 1083 Moore, J.L., Potter, K., Blankshain, K., Kaplan, S.L., O'Dwyer, L.C., and Sullivan, J.E. (2018). A
1084 Core Set of Outcome Measures for Adults With Neurologic Conditions Undergoing
1085 Rehabilitation: A CLINICAL PRACTICE GUIDELINE. *J Neurol Phys Ther* 42(3), 174-220.
1086 doi: 10.1097/NPT.0000000000000229.
- 1087 Morrison, S., Colberg, S.R., Mariano, M., Parson, H.K., and Vinik, A.I. (2010). Balance training
1088 reduces falls risk in older individuals with type 2 diabetes. *Diabetes Care* 33(4), 748-750. doi:
1089 10.2337/dc09-1699.
- 1090 Morrison, S., Simmons, R., Colberg, S.R., Parson, H.K., and Vinik, A.I. (2018). Supervised Balance
1091 Training and Wii Fit-Based Exercises Lower Falls Risk in Older Adults With Type 2
1092 Diabetes. *J Am Med Dir Assoc* 19(2), 185.e187-185.e113. doi: 10.1016/j.jamda.2017.11.004.
- 1093 Mustapa, A., Justine, M., Mohd Mustafah, N., Jamil, N., and Manaf, H. (2016). Postural Control and
1094 Gait Performance in the Diabetic Peripheral Neuropathy: A Systematic Review. *Biomed Res
Int* 2016, 9305025. doi: 10.1155/2016/9305025.
- 1095 National Heart, L.a.B.I. (2020). *Study Quality Assessment Tools* [Online]. Available:
1096 <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools> [Accessed 2020].
- 1097 Oddsson, L., Bisson, T., Cohen, H., Iloputaife, I., Koehler-McNicholas, S., Kung, D., et al. (2020a).
1098 A Wearable Sensory Neuroprosthesis to Improve Gait and Balance Function in Persons with
1099 Sensory Peripheral Neuropathy – the walk2Wellness Trial (1170). *Neurology* 94(15
1100 Supplement), 1170.
- 1101 Oddsson, L., Bisson, T., Cohen, H., Koehler-McNicholas, S., Kung, D., and Wrisley, D. (2019).
1102 "Slips and Falls and Record Snow in Minnesota: walk2wellness Clinical Trial Update", in:
1103 *AAPM&R Annual Assembly*. (San Antonio, Texas).
- 1104 Oddsson, L.I.E., Bisson, T., Cohen, H.S., Jacobs, L., Khoshnoodi, M., Kung, D., et al. (2020b). Gait
1105 and Balance Function Improves After 10 Weeks of Using a Wearable Sensory
1106 Neuroprosthesis in Persons with Peripheral Neuropathy and High Fall Risk - the
1107 walk2Wellness Trial. *medRxiv*, 2020.2008.2002.20166231. doi:
1108 10.1101/2020.08.02.20166231.
- 1109 Oddsson, L.I.E., Boissy, P., and Melzer, I. (2007). How to improve gait and balance function in
1110 elderly individuals—compliance with principles of training. *Eur Rev Aging Phys Act* Volume
1111 4(Issue 1), 15-23. doi: <https://doi.org/10.1007/s11556-007-0019-9>.
- 1112 Perera, S., Mody, S.H., Woodman, R.C., and Studenski, S.A. (2006). Meaningful change and
1113 responsiveness in common physical performance measures in older adults. *J Am Geriatr Soc*
1114 54(5), 743-749. doi: 10.1111/j.1532-5415.2006.00701.x.
- 1115 Podsiadlo, D., and Richardson, S. (1991). The timed "Up & Go": a test of basic functional mobility
1116 for frail elderly persons. *J Am Geriatr Soc* 39(2), 142-148. doi: 10.1111/j.1532-
1117 5415.1991.tb01616.x.
- 1118 Powell, L.E., and Myers, A.M. (1995). The Activities-specific Balance Confidence (ABC) Scale. *J
1119 Gerontol A Biol Sci Med Sci* 50A(1), M28-34.
- 1120 Ptito, A., Papa, L., Gregory, K., Folmer, R.L., Walker, W.C., Prabhakaran, V., et al. (2020). A
1121 Prospective, Multicenter Study to Assess the Safety and Efficacy of Translingual
1122 Neurostimulation Plus Physical Therapy for the Treatment of a Chronic Balance Deficit Due
1123 to Mild-to-Moderate Traumatic Brain Injury. *Neuromodulation*. doi: 10.1111/ner.13159.
- 1124 Purser, J.L., Weinberger, M., Cohen, H.J., Pieper, C.F., Morey, M.C., Li, T., et al. (2005). Walking
1125 speed predicts health status and hospital costs for frail elderly male veterans. *J Rehabil Res
1126 Dev* 42(4), 535-546. doi: 10.1682/jrrd.2004.07.0087.
- 1127 Quigley, P.A., Bulat, T., Schulz, B., Friedman, Y., Hart-Hughes, S., Richardson, J.K., et al. (2014).
1128 Exercise interventions, gait, and balance in older subjects with distal symmetric
- 1129

Wearable Sensory Neuroprosthesis for Balance

- 1130 polyneuropathy: a three-group randomized clinical trial. *Am J Phys Med Rehabil* 93(1), 1-12;
1131 quiz 13-16. doi: 10.1097/PHM.0000000000000052.
- 1132 Richardson, J.K., and Hurvitz, E.A. (1995). Peripheral neuropathy: a true risk factor for falls. *J
1133 Gerontol A Biol Sci Med Sci* 50(4), M211-215.
- 1134 Richardson, J.K., Sandman, D., and Vela, S. (2001). A focused exercise regimen improves clinical
1135 measures of balance in patients with peripheral neuropathy. *Arch Phys Med Rehabil* 82(2),
1136 205-209. doi: 10.1053/apmr.2001.19742.
- 1137 Rief, W., Nestoriuc, Y., Weiss, S., Welzel, E., Barsky, A.J., and Hofmann, S.G. (2009). Meta-
1138 analysis of the placebo response in antidepressant trials. *J Affect Disord* 118(1-3), 1-8. doi:
1139 10.1016/j.jad.2009.01.029.
- 1140 Riskowski, J.L., Quach, L., Manor, B., Menz, H.B., Lipsitz, L.A., and Hannan, M.T. (2012).
1141 Idiopathic peripheral neuropathy increases fall risk in a population-based cohort study of
1142 older adults. *Journal of Foot and Ankle Research* 5(1), P19. doi: 10.1186/1757-1146-5-S1-
1143 P19.
- 1144 Rossi-Izquierdo, M., Ernst, A., Soto-Varela, A., Santos-Pérez, S., Faraldo-García, A., Sesar-Ignacio,
1145 A., et al. (2013). Vibrotactile neurofeedback balance training in patients with Parkinson's
1146 disease: reducing the number of falls. *Gait Posture* 37(2), 195-200. doi:
1147 10.1016/j.gaitpost.2012.07.002.
- 1148 Salsabili, H., Bahrpeyma, F., and Esteki, A. (2015). The effects of Task-Oriented Motor Training on
1149 gait characteristics of patients with type 2 diabetes neuropathy. *J Diabetes Metab Disord* 15,
1150 14. doi: 10.1186/s40200-016-0236-8.
- 1151 Scheffer, A.C., Schuurmans, M.J., van Dijk, N., van der Hooft, T., and de Rooij, S.E. (2008). Fear of
1152 falling: measurement strategy, prevalence, risk factors and consequences among older
1153 persons. *Age Ageing* 37(1), 19-24. doi: 10.1093/ageing/afm169.
- 1154 Shumway-Cook, A., Brauer, S., and Woollacott, M. (2000). Predicting the probability for falls in
1155 community-dwelling older adults using the Timed Up & Go Test. *Phys Ther* 80(9), 896-903.
- 1156 Shumway-Cook, A., Gruber, W., Baldwin, M., and Liao, S. (1997). The effect of multidimensional
1157 exercises on balance, mobility, and fall risk in community-dwelling older adults. *Phys Ther*
1158 77(1), 46-57. doi: 10.1093/ptj/77.1.46.
- 1159 Sterling, D.A., O'Connor, J.A., and Bonadies, J. (2001). Geriatric falls: injury severity is high and
1160 disproportionate to mechanism. *J Trauma* 50(1), 116-119. doi: 10.1097/00005373-
1161 200101000-00021.
- 1162 Streckmann, F., Zopf, E.M., Lehmann, H.C., May, K., Rizza, J., Zimmer, P., et al. (2014). Exercise
1163 intervention studies in patients with peripheral neuropathy: a systematic review. *Sports Med*
1164 44(9), 1289-1304. doi: 10.1007/s40279-014-0207-5.
- 1165 Strzalkowski, N.D.J., Peters, R.M., Inglis, J.T., and Bent, L.R. (2018). Cutaneous afferent
1166 innervation of the human foot sole: what can we learn from single-unit recordings? *J
1167 Neurophysiol* 120(3), 1233-1246. doi: 10.1152/jn.00848.2017.
- 1168 Studenski, S., Perera, S., Patel, K., Rosano, C., Faulkner, K., Inzitari, M., et al. (2011). Gait speed
1169 and survival in older adults. *JAMA* 305(1), 50-58. doi: 10.1001/jama.2010.1923.
- 1170 Studenski, S., Perera, S., Wallace, D., Chandler, J.M., Duncan, P.W., Rooney, E., et al. (2003).
1171 Physical performance measures in the clinical setting. *J Am Geriatr Soc* 51(3), 314-322. doi:
1172 10.1046/j.1532-5415.2003.51104.x.
- 1173 Tinetti, M.E., and Kumar, C. (2010). The patient who falls: "It's always a trade-off". *JAMA* 303(3),
1174 258-266. doi: 10.1001/jama.2009.2024.
- 1175 Toftaglen, C., Visovsky, C., and Berry, D.L. (2012). Strength and balance training for adults with
1176 peripheral neuropathy and high risk of fall: current evidence and implications for future
1177 research. *Oncol Nurs Forum* 39(5), E416-424. doi: 10.1188/12.ONF.E416-E424.

Wearable Sensory Neuroprosthesis for Balance

- 1178 Tyler, M., Danilov, Y., and Bach-Y-Rita, P. (2003). Closing an open-loop control system: vestibular
1179 substitution through the tongue. *J Integr Neurosci* 2(2), 159-164.
1180 Uitenbroek, D.G. (1997). *SISA-Binomial* [Online]. Available:
1181 <https://www.quantitativeskills.com/sisa/calculations/bonfer.htm> [Accessed May 2020].
1182 Vinik, A.I., Camacho, P., Reddy, S., Valencia, W.M., Treince, D., Matsumoto, A.M., et al. (2017).
1183 AGING, DIABETES, AND FALLS. *Endocr Pract* 23(9), 1117-1139. doi:
1184 10.4158/EP171794.RA.
1185 Wall, C., Wrisley, D., and Oddsson, L. (2012). Vibrotactile feedback of mediolateral trunk tilt or foot
1186 pressure increases locomotor performance in healthy older adults--a pilot study. *Conf Proc
1187 IEEE Eng Med Biol Soc* 2012, 6145-6148. doi: 10.1109/EMBC.2012.6347396.
1188 Wall, C., Wrisley, D.M., and Statler, K.D. (2009). Vibrotactile tilt feedback improves dynamic gait
1189 index: a fall risk indicator in older adults. *Gait Posture* 30(1), 16-21. doi:
1190 10.1016/j.gaitpost.2009.02.019.
1191 Wang, C., Goel, R., Rahemi, H., Zhang, Q., Lepow, B., and Najafi, B. (2019a). Effectiveness of
1192 Daily Use of Bilateral Custom-Made Ankle-Foot Orthoses on Balance, Fear of Falling, and
1193 Physical Activity in Older Adults: A Randomized Controlled Trial. *Gerontology* 65(3), 299-
1194 307. doi: 10.1159/000494114.
1195 Wang, C., Goel, R., Zhang, Q., Lepow, B., and Najafi, B. (2019b). Daily Use of Bilateral Custom-
1196 Made Ankle-Foot Orthoses for Fall Prevention in Older Adults: A Randomized Controlled
1197 Trial. *J Am Geriatr Soc* 67(8), 1656-1661. doi: 10.1111/jgs.15929.
1198 Wartolowska, K.A., Feakins, B.G., Collins, G.S., Cook, J., Judge, A., Rombach, I., et al. (2016). The
1199 magnitude and temporal changes of response in the placebo arm of surgical randomized
1200 controlled trials: a systematic review and meta-analysis. *Trials* 17(1), 589. doi:
1201 10.1186/s13063-016-1720-7.
1202 Winters-Stone, K.M., Horak, F., Jacobs, P.G., Trubowitz, P., Dieckmann, N.F., Stoyles, S., et al.
1203 (2017). Falls, Functioning, and Disability Among Women With Persistent Symptoms of
1204 Chemotherapy-Induced Peripheral Neuropathy. *J Clin Oncol* 35(23), 2604-2612. doi:
1205 10.1200/JCO.2016.71.3552.
1206 Wolf, B., Feys, H., De Weerdt, van der Meer, J., Noom, M., and Aufdemkampe, G. (2001). Effect of
1207 a physical therapeutic intervention for balance problems in the elderly: a single-blind,
1208 randomized, controlled multicentre trial. *Clin Rehabil* 15(6), 624-636. doi:
1209 10.1191/0269215501cr456oa.
1210 Wolf, S.L., Barnhart, H.X., Kutner, N.G., McNeely, E., Coogler, C., and Xu, T. (1996). Reducing
1211 frailty and falls in older persons: an investigation of Tai Chi and computerized balance
1212 training. Atlanta FICSIT Group. Frailty and Injuries: Cooperative Studies of Intervention
1213 Techniques. *J Am Geriatr Soc* 44(5), 489-497. doi: 10.1111/j.1532-5415.1996.tb01432.x.
1214 Wolf, S.L., Sattin, R.W., Kutner, M., O'Grady, M., Greenspan, A.I., and Gregor, R.J. (2003). Intense
1215 tai chi exercise training and fall occurrences in older, transitioningally frail adults: a randomized,
1216 controlled trial. *J Am Geriatr Soc* 51(12), 1693-1701. doi: 10.1046/j.1532-
1217 5415.2003.51552.x.
1218 Woolcott, J.C., Richardson, K.J., Wiens, M.O., Patel, B., Marin, J., Khan, K.M., et al. (2009). Meta-
1219 analysis of the impact of 9 medication classes on falls in elderly persons. *Arch Intern Med*
1220 169(21), 1952-1960. doi: 10.1001/archinternmed.2009.357.
1221 Wrisley, D., McLean, G., and Lars, O. (Year). "The Use of a Wearable Sensory Prosthesis to
1222 Improve Gait and Balance in a Patient with Peripheral Neuropathy", in: *APTA Combined
1223 Sections Meeting*, #3196.

Wearable Sensory Neuroprosthesis for Balance

- 1224 Wrisley, D.M., and Kumar, N.A. (2010). Functional gait assessment: concurrent, discriminative, and
1225 predictive validity in community-dwelling older adults. *Phys Ther* 90(5), 761-773. doi:
1226 10.2522/ptj.20090069.
- 1227 Wrisley, D.M., Marchetti, G.F., Kuharsky, D.K., and Whitney, S.L. (2004). Reliability, internal
1228 consistency, and validity of data obtained with the functional gait assessment. *Phys Ther*
1229 84(10), 906-918.
- 1230 Yamanaka, T., Sawai, Y., Murai, T., Nishimura, T., and Kitahara, T. (2016). Long-term effects of
1231 electrotactile sensory substitution therapy on balance disorders. *Neuroreport* 27(10), 744-748.
1232 doi: 10.1097/WNR.0000000000000606.
- 1233 Zaiontz, C. (2020). *Real Statistics Resource Pack (Release 6.8)* [Online]. Available:
1234 <http://www.real-statistics.com/> [Accessed].
- 1235 Zehr, E.P., Nakajima, T., Barss, T., Klarner, T., Miklosovic, S., Mezzarane, R.A., et al. (2014).
1236 Cutaneous stimulation of discrete regions of the sole during locomotion produces "sensory
1237 steering" of the foot. *BMC Sports Sci Med Rehabil* 6, 33. doi: 10.1186/2052-1847-6-33.
- 1238 Zehr, E.P., and Stein, R.B. (1999). What functions do reflexes serve during human locomotion? *Prog
1239 Neurobiol* 58(2), 185-205. doi: 10.1016/s0301-0082(98)00081-1.
- 1240